Northwest Biotherapeutics (NWBO) 10-K 16 Mar 16 2015 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2015	Mar. 10, 2016	Jun. 30, 2015
Document Information [Line Items]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	FY
Entity Registrant Name	NORTHWEST BIOTHERAPEUTICS INC
Entity Central Index Key	1,072,379
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Public Float			$ 244,870,374
Trading Symbol	NWBO
Entity Common Stock, Shares Outstanding		101,740,440

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 21,813	$ 13,390
Restricted cash - interest payments held in escrow	886	865
Prepaid expenses and other current assets	1,402	387
Total current assets	24,101	14,642
Non-current assets:
Property, plant and equipment, net	46,157	39,999
Restricted cash - interest payments held in escrow, net of current portion	349	1,760
Other assets	190	55
Total non-current assets	46,696	41,814
Total assets	70,797	56,456
Current liabilities:
Accounts payable	11,721	9,826
Accounts payable to related party	5,455	5,729
Accrued expenses (includes related party of $11 and $8 as of December 31, 2015 and December 31, 2014, respectively)	1,309	1,211
Convertible notes, net (includes related party note of $50 and $50 as of December 31, 2015 and December 31, 2014, respectively)	185	238
Note payable - in dispute	934	934
Mortgage loan (net of deferred financing cost of $468 and $862 as of December 31, 2015 and December 31, 2014, respectively)	11,003	6,128
Environmental remediation liability	6,200	6,200
Derivative liability	27,982	44,742
Total current liabilities	64,789	75,008
Non-current liabilities:
Convertible note (net of deferred financing cost of $457 and $1,123 as of December 31, 2015 and December 31, 2014, respectively)	10,543	16,377
Other accrued expenses	141	98
Total non-current liabilities	10,684	16,475
Total liabilities	$ 75,473	$ 91,483
Commitments and Contingencies
Stockholders' equity (deficit):
Preferred stock ($0.001 par value); 40,000,000 shares authorized; 0 shares issued and outstanding as of December 31, 2015 and December 31, 2014, respectively	$ 0	$ 0
Common stock ($0.001 par value); 450,000,000 shares authorized; 95,858,087 and 68,957,469 shares issued and outstanding as of December 31, 2015 and December 31, 2014, respectively	96	69
Additional paid-in capital	630,613	485,615
Accumulated deficit	(635,262)	(520,521)
Accumulated other comprehensive loss	(123)	(190)
Total stockholders' equity (deficit)	(4,676)	(35,027)
Total liabilities and stockholders' equity (deficit)	$ 70,797	$ 56,456

CONSOLIDATED BALANCE SHEETS _Pa

CONSOLIDATED BALANCE SHEETS [Parenthetical] - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Accrued expenses, related party net (in dollars)	$ 11	$ 8
Convertible notes payable current related parties, net (in dollars)	$ 50	$ 50
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	40,000,000	40,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	450,000,000	450,000,000
Common stock, shares issued	95,858,087	68,957,469
Common stock, shares outstanding	95,858,087	68,957,469
Convertible Debt [Member]
Deferred Finance Costs, Noncurrent, Net (in dollars)	$ 457	$ 1,123
Mortgage Loan [Member]
Deferred Finance Costs, Noncurrent, Net (in dollars)	$ 468	$ 862

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Revenues:
Research grant and other	$ 1,739	$ 1,454	$ 809
Total revenues	1,739	1,454	809
Operating costs and expenses:
Research and development	103,120	85,637	43,906
General and administrative	24,903	16,960	12,377
Total operating costs and expenses	128,023	102,597	56,283
Loss from operations	(126,284)	(101,143)	(55,474)
Other income (expense):
Inducement expense	0	(18,905)	(10,599)
Accretion of redeemable securities	0	0	(31)
Change in fair value of derivative liability	15,676	(15,062)	1,157
Interest expense	(4,153)	(996)	(842)
Section 16 settlement	0	449	0
Foreign currency transaction gain	20	23	0
Net loss	$ (114,741)	$ (135,634)	$ (65,789)
Net earnings (loss) per share applicable to common stockholders
Net loss per share applicable to common stockholders - basic and diluted (in dollars per share)	$ (1.48)	$ (2.29)	$ (2)
Weighted average shares used in computing basic and diluted loss per share (in shares)	77,713	59,248	32,865

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Net loss	$ (114,741)	$ (135,634)	$ (65,789)
Other comprehensive income (loss)
Foreign currency translation adjustment	67	0	(190)
Total comprehensive loss	$ (114,674)	$ (135,634)	$ (65,979)

CONSOLIDATED STATEMENTS OF CHAN

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Cumulative Translation Adjustment [Member]
Balance at Dec. 31, 2012	$ (16,073)	$ 25	$ 303,190	$ (319,098)	$ (190)
Balance (in shares) at Dec. 31, 2012		24,677
Exercise of warrants	595	$ 1	594	0	0
Exercise of warrants (in Shares)		347
Issuance of common stock in connection with conversion of notes payable	2,869	$ 2	2,867	0	0
Issuance of common stock in connection with conversion of notes payable (in shares)		1,211
Stock and warrants issued to induce an extension of redeemable securities	2,804	$ 1	2,803	0	0
Stock and warrants issued to induce an extension of redeemable securities (in shares)		763
Reclassification of redeemable shares to stockholders' equity	1,864	$ 1	1,863	0	0
Reclassification of redeemable shares to stockholders' equity (in shares)		424
Reclass of warrants to warrant liability	(217)	$ 0	(217)	0	0
Issuance of common stock in connection with conversion of accounts payable - Cognate BioServices	16,969	$ 5	16,964	0	0
Issuance of common stock in connection with conversion of accounts payable - Cognate BioServices (in shares)		4,720
Issuance of common stock for cash	53,026	$ 13	53,013	0	0
Issuance of common stock for cash (in shares)		12,954
Reclassification between common par and additional paid-in-capital	0	$ (3)	3	0	0
Issuance of common stock in exchange for services - non-employees	2,341	$ 1	2,340	0	0
Issuance of common stock in exchange for services - non-employees (in shares)		570
Warrant liability recorded in connection with issuance of common stock	(5,602)	$ 0	(5,602)	0	0
Offering costs	(3,955)	0	(3,955)	0	0
Stock compensation expense	1,350	0	1,350	0	0
Net loss	(65,789)	0	0	(65,789)	0
Balance at Dec. 31, 2013	(9,818)	$ 46	375,213	(384,887)	(190)
Balance (in shares) at Dec. 31, 2013		45,666
Redeemable securities settlement	398	$ 0	398	0	0
Redeemable securities settlement (in shares)		110
Proceeds from warrants exercises	4,817	$ 1	4,816	0	0
Proceeds from warrants exercises (in shares)		1,311
Cashless warrants exercise	0	$ 0	0	0	0
Cashless warrants exercise (in shares)		54
Reclassification of redeemable shares to stockholders' equity	8,913	$ 1	8,912	0	0
Reclassification of redeemable shares to stockholders' equity (in shares)		1,445
Issuance of common stock in connection with conversion of accounts payable - Cognate BioServices	16,781	$ 5	16,776	0	0
Issuance of common stock in connection with conversion of accounts payable - Cognate BioServices (in shares)		4,195
Issuance of common stock for cash	15,000	$ 2	14,998	0	0
Issuance of common stock for cash (in shares)		2,273
Issuance of common stock for cash in a private placement	2,059	$ 0	2,059	0	0
Issuance of common stock for cash in a private placement (in shares)		291
Issuance of common stock in exchange for services - non-employees	1,817	$ 0	1,817	0	0
Issuance of common stock in exchange for services - non-employees (in shares)		279
Offering costs	(1,105)	$ 0	(1,105)	0	0
Inducement expenses associated with Conversion of accounts payable to common stock and warrants - Cognate BioServices	8,654	0	8,654	0	0
Conversion of note payable and accrued interest to common stock	217	$ 0	217	0	0
Conversion of note payable and accrued interest to common stock (in shares)		70
Proceeds from the issuance of common stock - Cognate BioServices	2,250	$ 1	2,249	0	0
Proceeds from the issuance of common stock - Cognate BioServices (in shares)		563
Issuance of common stock and warrants for cash	40,235	$ 8	40,227
Issuance of common stock and warrants for cash (in shares)		7,490
Issuance of common stock as deferred financing cost - mortgage loan	197	$ 0	197
Adjustment for issuance of common stock	2	0	2	0	0
Stock based compensation - Cognate BioServices	8,665	$ 5	8,660	0	0
Stock based compensation - Cognate BioServices (in shares)		5,101
Stock issued to Cognate BioServices as compensation under Cognate Agreements	1,525	$ 0	1,525	0	0
Net loss	(135,634)	$ 0	0	(135,634)	0
Adjustment for issuance of common stock (in shares)		71
Issuance of common stock as deferred financing cost - mortgage loan (in shares)		38
Balance at Dec. 31, 2014	(35,027)	$ 69	485,615	(520,521)	(190)
Balance (in shares) at Dec. 31, 2014		68,957
Proceeds from issuance of common stock, net of offering cost	81,662	$ 14	81,648	0	0
Proceeds from issuance of common stock, net of offering cost (in shares)		14,360
Redeemable securities settlement	299	$ 0	299	0	0
Redeemable securities settlement (in shares)		80
Issuance of common stock for debt conversion	6,500	$ 1	6,499	0	0
Issuance of common stock for debt conversion (in shares)		985
Issuance of common stock for conversion of accrued interest	387	$ 0	387	0	0
Issuance of common stock for conversion of accrued interest (in Shares)		39
Proceeds from warrants exercises	7,430	$ 2	7,428	0	0
Proceeds from warrants exercises (in shares)		1,728
Reclassification of warrant liabilities related to warrants exercised for cash	264	$ 0	264	0	0
Cashless warrants exercise	521	$ 1	520	0	0
Cashless warrants exercise (in shares)		572
Issuance of common stock in connection with conversion of accounts payable - Cognate BioServices	3,751	$ 1	3,750	0	0
Issuance of common stock in connection with conversion of accounts payable - Cognate BioServices (in shares)		682
Stock based compensation - Cognate BioServices	40,765	$ 8	40,757	0	0
Stock based compensation - Cognate BioServices (in shares)		8,052
Common stock issued for services	3,389	$ 0	3,389	0	0
Common stock issued for services (in Shares)		403
Issuance of warrants in conjunction with demand notes	57	$ 0	57	0	0
Net loss	(114,741)	0	0	(114,741)	0
Cumulative translation adjustment	67	0	0	0	67
Balance at Dec. 31, 2015	$ (4,676)	$ 96	$ 630,613	$ (635,262)	$ (123)
Balance (in shares) at Dec. 31, 2015		95,858

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Cash Flows from Operating Activities:
Net Loss	$ (114,741)	$ (135,634)	$ (65,789)
Reconciliation of net loss to net cash used in operating activities:
Depreciation and amortization	56	11	11
Amortization of debt discount and accretion on redeemable securities	57	0	531
Amortization of deferred financing cost	1,248	212	0
Change in fair value of derivatives	(15,676)	15,062	(1,157)
Gain from section 16 settlement	0	(449)	0
Accrued interest converted to common stock	0	77	0
Stock and warrants issued to Cognate BioServices as compensation under Cognate Agreements	40,765	21,329	0
Stock-based compensation costs	0	0	1,350
Stock and warrants issued for services	3,389	1,819	2,341
Inducement expense	0	18,905	10,599
Correction on debt from prior period	(53)	0	0
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(478)	(240)	(35)
Accounts payable and accrued expenses	3,912	4,989	766
Related party accounts payable and accrued expenses	3,048	19,343	13,754
Deposits and other non-current assets	(135)	0	(37)
Net cash used in operating activities	(78,608)	(54,576)	(37,800)
Cash Flows from Investing Activities:
Purchase of property, plant and equipment	(6,751)	(33,727)	1
Funding of escrow - convertible notes	0	(2,625)	0
Net cash (used in) provided by investing activities	(6,751)	(36,352)	1
Cash Flows from Financing Activities:
Proceeds from issuance of notes payable to related parties	1,400	0	1,630
Repayment of notes payable to related parties	(1,400)	(25)	(1,605)
Repayment of convertible promissory notes	0	0	(499)
Proceeds from mortgage loan	4,997	6,990	0
Deferred offering cost related to mortgage loan	(138)	(622)	0
Proceeds transferred from escrow account	287	0
Proceeds from issuance of convertible notes, net of deferred financing cost	0	17,500	0
Deferred offering cost related to convertible notes	0	(1,280)	0
Redemption of redeemable common shares	0	0	(240)
Proceeds from issuance of common stock in a private placement	0	2,059	0
Proceeds from exercise of warrants	7,430	4,817	595
Proceeds from the issuance of common stock and warrants - Cognate	0	2,250	0
Proceeds from issuance common stock and warrants, net of offering cost	81,662	40,235	53,026
Proceeds from issuance common stock and overallotment rights, net of offering cost	0	13,895	0
Offering costs	0	0	(3,955)
Net cash provided by financing activities	94,238	85,819	48,952
Effect of exchange rate changes on cash and cash equivalents	(456)	0	0
Net increase (decrease) in cash and cash equivalents	8,423	(5,109)	11,153
Cash and cash equivalents at beginning of year	13,390	18,499	7,346
Cash and cash equivalents at end of year	21,813	13,390	18,499
Supplemental schedule of non-cash investing and financing activities:
Issuance of warrants in conjunction with demand notes	57	0
Reclass of redeemable security to equity	0	8,913	217
Adjustment for common stock no longer subject to redemption	0	0	1,864
Deferred offering cost related to mortgage loan	51	98	0
Environmental remediation liabilities	0	6,200	0
Reclassification of warrant liabilities related to cashless warrants exercise	521	0	0
Reclassification of warrant liabilities related to warrants exercised for cash	264	0	0
Issuance of common stock for debt conversion	6,500	0	0
Issuance of common stock for conversion of accrued interest	387	0	0
VAT receivable related to UK facility	537	0	0
Redeemable security settlement	299	0	0
Mortgage Loan [Member]
Supplemental disclosure of cash flow information
Interest Payments	(1,369)	(70)	0
Supplemental schedule of non-cash investing and financing activities:
Issuance of common stock	0	197	0
Notes Payable and Accrued Expenses [Member]
Supplemental schedule of non-cash investing and financing activities:
Issuance of common stock	0	217	2,869
Convertible Notes Payable [Member]
Supplemental disclosure of cash flow information
Interest Payments	(1,103)	0	0
Cognate Bioservices [Member]
Reconciliation of net loss to net cash used in operating activities:
Stock-based compensation costs	40,800	21,300	2,300
Supplemental schedule of non-cash investing and financing activities:
Issuance of common stock and warrants in connection with conversion of accounts payable - Cognate BioServices	$ 3,751	$ 16,781	$ 16,968

Organization and Description of

Organization and Description of Business	12 Months Ended
	Dec. 31, 2015
Organization, Consolidation and Presentation Of Financial Statements [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. Organization and Description of Business Northwest Biotherapeutics, Inc. and its wholly owned subsidiaries NW Bio Gmbh, and Aracaris Capital, Ltd (collectively, the “Company”, “we”, “us” and “our”) were organized to discover and develop innovative immunotherapies for cancer. The Company is developing an experimental dendritic cell vaccine using its platform technology known as DCVax. DCVax is currently being tested for use in the treatment of certain types of cancers. The Company is currently conducting clinical trials in more than 60 trial sites in the United States and Europe. Cognate BioServices, Inc. (“Cognate BioServices”), which is a company related by common ownership (Note 9), provides the Company with mission critical contract manufacturing services, research and development services, distribution and logistics, and related services, in compliance with the Company’s specifications and the applicable regulatory requirements for clinical grade cellular products. The Company and Cognate BioServices are currently parties to a series of contracts providing for these services as more fully described below. The Company is dependent on Cognate BioServices to provide the manufacturing services, and any interruption of such services could potentially have a material adverse effect on the Company’s ability to proceed with its clinical trials. Cognate BioServices’ manufacturing facility for clinical-grade cellular products is located in Memphis, Tennessee, a major air cargo hub for both Federal Express and UPS. Although there are many contract manufacturers for small molecule drugs and for biologics, there are only a few contract manufacturers in the U.S., and even fewer in Europe, that specialize in producing living cell products and that have a track record of success with regulatory authorities. The manufacturing of living cell products is highly specialized and entirely different than production of biologics: the physical facilities and equipment are different, the types of personnel and skill sets are different, and the processes are different. The regulatory requirements relating to manufacturing and cellular products are especially challenging and are one of the most frequent reasons for the development of a company’s cellular products to be put on clinical hold (i.e., stopped by regulatory authorities). In addition, NW Bio’s programs require a large amount of capacity in these specialized manufacturing facilities, and require that the large capacity be dedicated exclusively to NW Bio’s programs. Most medical products, including cellular products, are made in batches on a “campaign” basis: the same manufacturing suites are used for a number of companies’ products, at designated times scheduled in advance. In contrast, NW Bio’s products are fully personalized and not made in batches, and NW Bio’s products are made on demand, on an ongoing basis. So, the manufacturing suites must be dedicated entirely to NW Bio’s products. Among the few specialized contract manufacturers for cellular products, even fewer have the necessary capacity that can be dedicated exclusively to NW Bio.

Liquidity, Financial Condition

Liquidity, Financial Condition and Management Plans	12 Months Ended
	Dec. 31, 2015
Liquidity [Abstract]
Liquidity and Financial Condition [Text Block]	2. Liquidity, Financial Condition and Management Plans The Company used approximately $ 78.6 114.7 29.8 On January 17, 2014, the Company entered into a series of contract manufacturing and services agreements with Cognate BioServices (collectively, the “Cognate Agreements” or the “Agreements”) providing for Cognate BioServices to manufacture DCVax products, undertake ongoing DCVax development work, develop arrangements for and manage product storage, distribution and tracking, and conduct search, evaluation, acquisition and development activities for expansion of manufacturing capacity for NW Bio products. By entering into the Cognate Agreements, cash outflows related to research and development were greatly reduced. In addition, because the payments were made in unregistered, restricted shares, and were also subject to a lock-up, the shares did not come into the marketplace. The Company had current assets of $ 24.1 40.7 28.0 40.7 5.5 Because of recurring operating losses, net operating cash flow deficits, and an accumulated deficit, there is substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements have been prepared assuming that the Company will continue as a going concern, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets, or the amounts and classification of liabilities that may result from the outcome of this uncertainty.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	3. Summary of Significant Accounting Policies The accompanying consolidated financial statements of the Company were prepared in accordance with generally accepted accounting principles in the U.S. (“U.S. GAAP”) and include the assets, liabilities, revenues and expenses of the wholly owned subsidiaries in Germany, Switzerland and the United Kingdom. All intercompany transactions and accounts have been eliminated in consolidation. Cash consists of funds deposited in checking accounts. While cash held by financial institutions may at times exceed federally insured limits, management believes that no material credit or market risk exposure exists due to the high credit quality of the institutions that have custody of the Company’s funds. The Company has not incurred any losses on such accounts. Property and equipment are stated at cost. Depreciation and amortization are provided for using straight-line methods, in amounts sufficient to charge the cost of depreciable assets to operations over their estimated service lives. The UK Property’s building will be depreciated over 15 The fair value of financial instruments other than liabilities payable to related parties approximate the recorded value based on the short term nature of these financial instruments. The fair value of derivative liabilities is measured using a binomial model or Monte Carlo simulation depending on the complexity of the derivative (Note 4). The Company capitalizes costs related to the issuance of debt which are included on the accompanying consolidated balance sheets. Deferred financing costs are amortized using a method that approximates the interest method over the life of the related loan and are included as a component of interest expense on the accompanying consolidated statements of operations. As of December 31, 2015, deferred financing costs were $ 0.9 1.2 The Company accounts for the 12,433,310 The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. In performing a review for impairment, the Company compares the carrying value of the assets with its estimated future undiscounted cash flows from the use of the asset and eventual disposition. If the estimated undiscounted future cash flows are less than carrying value, an impairment loss is charged to operations based on the difference between the carrying amount and the fair value of the asset. The Company records environmental remediation liabilities for properties acquired. The environmental remediation liabilities are initially recorded at fair value. The liability is reduced for actual costs incurred in connection with the clean-up activities for each property. Upon completion of the clean-up, the environmental remediation liability is adjusted to equal the fair value of the remaining operation, maintenance and monitoring activities to be performed for the property. The reduction in the liability resulting from the completion of the clean-up is included in other income. As of December 31, 2015, we estimate that the total environmental remediation costs associated with the purchase of the UK Facility will amount to approximately $ 6.2 $ 6.2 $ 4.5 $ 32.0 The Company has operations in Germany, the United Kingdom and Canada, in addition to the U.S. Assets and liabilities are translated into U.S. dollars using end of period exchange rates and revenues and expenses are translated into U.S. dollars using weighted average rates. Foreign currency translation adjustments are reported as a separate component of accumulated other comprehensive income (loss) within stockholders’ equity (deficit). During the year ended December 31, 2015, the Company recorded $ 67 Foreign currency transaction gains and losses are recognized in the Consolidated Statements of Operations as incurred. The Company reports comprehensive loss and its components in its consolidated financial statements. Comprehensive loss consists of net loss and foreign currency translation adjustments, affecting stockholders’ equity (deficit) that, under U.S, GAAP, is excluded from net loss. The Company recognizes revenue in accordance with the terms stipulated under the patient service contract. In various situations, the Company receives certain payments for DCVax®-L for patient treatment. These payments are non-refundable, and are not dependent on the Company’s ongoing future performance. The Company has adopted a policy of recognizing these payments as revenue when received. Substantial portions of our preclinical studies and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors (collectively "CROs"). These CROs generally bill monthly or quarterly for services performed, or bill based upon milestones achieved. For clinical studies, expenses are accrued based upon the number of patients enrolled and the duration of the study. The Company monitors patient enrollment, the progress of clinical studies and related activities through internal reviews of data that is tracked by the CROs under contractual arrangements, correspondence with the CROs and visits to clinical sites. Research and development costs are charged to operations as incurred and consist primarily of clinical trial costs, related party manufacturing costs, consulting costs, contract research and development costs, and compensation costs. For the years ended December 31, 2015, 2014 and 2013, the Company recognized research and development costs of $ 103.1 85.6 43.9 During 2014 and 2013, the Company paid a substantial portion of Cognate’s invoices in stock rather than in cash; during 2015, the Company mostly paid Cognate’s invoices in cash. At December 31, 2015 and 2014, the Company owed Cognate BioServices $ 5.5 5.7 During the years ended December 31, 2015, 2014 and 2013, the Company incurred non-cash equity based compensation (restricted common stock and warrants) related to Cognate BioServices of $ 40.8 million, $ 21.3 0 The Company incurred research and development costs related to Cognate BioServices of $ 78.5 61.0 26.8 The Company recognizes income taxes on an accrual basis based on tax positions taken or expected to be taken in its tax returns. A tax position is defined as a position in a previously filed tax return or a position expected to be taken in a future tax filing that is reflected in measuring current or deferred income tax assets and liabilities. Tax positions are recognized only when it is more likely than not (i.e., likelihood of greater than 50%), based on technical merits, that the position would be sustained upon examination by taxing authorities. Tax positions that meet the more likely than not threshold are measured using a probability-weighted approach as the largest amount of tax benefit that is greater than 50% likely of being realized upon settlement. Income taxes are accounted for using an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in our financial statements or tax returns. A valuation allowance is established to reduce deferred tax assets if all, or some portion, of such assets will more than likely not be realized. Should they occur, our policy is to classify interest and penalties related to tax positions as income tax expense. Since our inception, no such interest or penalties have been incurred, however prior to 1998 the Company was a limited liability company and the Company’s tax losses and credits generally flowed directly to the members. The Company accounts for stock based compensation awards issued to non-employees for services, as prescribed by ASC 505, at either the fair value of the services or the instruments issued in exchange for such services (based on the same methodology described for employee stock based compensation), whichever is more readily determinable. Subsequent to the measurement date, the Company recognizes and classifies any future changes in the fair value in accordance with the relevant accounting literature on financial instruments ASC 815-40. In preparing financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. These estimates and assumptions include valuing equity securities in share-based payment arrangements, estimating the fair value of equity instruments recorded as derivative liabilities, useful lives of depreciable assets and whether impairment charges may apply, and the fair value of environmental remediation liabilities. Basic loss per share is computed on the basis of the weighted average number of shares outstanding for the reporting period. Diluted loss per share is computed on the basis of the weighted average number of common shares (including redeemable shares) plus dilutive potential common shares outstanding using the treasury stock method. Any potentially dilutive securities are anti-dilutive due to the Company’s net losses. For the years presented, there is no difference between the basic and diluted net loss per share. The Company operates in one reportable segment and, accordingly, no segment disclosures have been presented herein. The Company follows the provisions of ASC Topic 855-10, “Subsequent Events,” relating to subsequent events. This guidance establishes principles and requirements for subsequent events. This guidance defines the period after the balance sheet date during which events or transactions that may occur would be required to be disclosed in a company’s financial statements. The Company has evaluated subsequent events up to the date of filing of its Annual Report on Form 10-K for the year ended December 31, 2015 (see Note (13). In August 2015, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2015-15, “Interest - Imputation of Interest: Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements”, which clarifies the treatment of debt issuance costs from line-of-credit arrangements after the adoption of ASU No. 2015-03, “Interest - Imputation of Interest: Simplifying the Presentation of Debt Issuance Costs”. In particular, ASU No. 2015-15 clarifies that the SEC staff would not object to an entity deferring and presenting debt issuance costs related to a line-of-credit arrangement as an asset and subsequently amortizing the deferred debt issuance costs ratably over the term of such arrangement, regardless of whether there are any outstanding borrowings on the line-of-credit arrangement. The Company adopted ASU No. 2015-15 during the first quarter of fiscal 2016, and its adoption did not have a material impact on its condensed financial statements. In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers”, an updated standard on revenue recognition. ASU No. 2014-09 provides enhancements to the quality and consistency of how revenue is reported by companies while also improving comparability in the financial statements of companies reporting using International Financial Reporting Standards or U.S. GAAP. The main purpose of the new standard is for companies to recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration to which a company expects to be entitled in exchange for those goods or services. The new standard also will result in enhanced disclosures about revenue, provide guidance for transactions that were not previously addressed comprehensively and improve guidance for multiple-element arrangements. In July 2015, the FASB voted to approve a one-year deferral of the effective date of ASU No. 2014-09, which will be effective for the Company in the first quarter of fiscal year 2018 and may be applied on a full retrospective or modified retrospective approach. The Company is evaluating the impact of implementation and transition approach of this standard on its financial statements. In August 2014, the FASB issued ASU No. 2014-15, “Presentation of Financial Statements-Going Concern”, which defines management's responsibility to assess an entity's ability to continue as a going concern, and requires related footnote disclosures if there is substantial doubt about its ability to continue as a going concern. ASU No. 2014-15 is effective for the Company for the fiscal year ending on December 31, 2016, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU No. 2014-15 and its related disclosures. In November 2015, FASB issued ASU No. 2015-17, “Balance Sheet Classification of Deferred Taxes”. ASU No. 2015-17 requires that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. ASU No. 2015-17 is effective for financial statements issued for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. The Company is currently evaluating the impact that ASU No. 2015-17 will have on its balance sheet and financial statement disclosures. In January 2016, FASB issued ASU No. 2016-01, “Recognition and Measurement of Financial Assets and Financial Liabilities”. ASU No. 2016-01 requires equity investments to be measured at fair value with changes in fair value recognized in net income; simplifies the impairment assessment of equity investments without readily determinable fair values by requiring a qualitative assessment to identify impairment; eliminates the requirement for public business entities to disclose the method(s) and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost on the balance sheet; requires public business entities to use the exit price notion when measuring the fair value of financial instruments for disclosure purposes; requires an entity to present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting from a change in the instrument-specific credit risk when the entity has elected to measure the liability at fair value in accordance with the fair value option for financial instruments; requires separate presentation of financial assets and financial liabilities by measurement category and form of financial assets on the balance sheet or the accompanying notes to the financial statements and clarifies that an entity should evaluate the need for a valuation allowance on a deferred tax asset related to available-for-sale securities in combination with the entity’s other deferred tax assets. ASU No. 2016-01 is effective for financial statements issued for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The Company is currently evaluating the impact that ASU No. 2016-01 will have on its financial statements and related disclosures. On February 25, 2016, FASB issued its new lease accounting guidance in Accounting Standards Update (ASU) No. 2016-02, Leases (Topic 842). Under the new guidance, lessees will be required to recognize for all leases (with the exception of short-term leases) a lease liability, which is a lessee‘s obligation to make lease payments arising from a lease, measured on a discounted basis and a right-of-use asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset for the lease term. The new standard is effective for fiscal year beginning after December 15, 2018, including interim periods within those fiscal years (i.e. a January 1, 2019 effective date). The Company is currently evaluating the effect the guidance will have on its consolidated financial statements.

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	4. Fair Value Measurements Fair value measured at December 31, 2015 Quoted prices in active Significant other Significant Fair value at markets observable inputs unobservable inputs December 31, 2015 (Level 1) (Level 2) (Level 3) Derivative liability $ 27,982 $ - $ - $ 27,982 Fair value measured at December 31, 2014 Quoted prices in active Significant other Significant Fair value at markets observable inputs unobservable inputs December 31, 2014 (Level 1) (Level 2) (Level 3) Derivative liability $ 44,742 $ - $ - $ 44,742 There were no transfers between Level 1, 2 or 3 during the years ended December 31, 2015 and 2014. The following table presents additional information about Level 3 liabilities measured at fair value. Both observable and unobservable inputs may be used to determine the fair value of positions that the Company has classified within the Level 3 category. As a result, the unrealized gains and losses for assets and liabilities within the Level 3 category may include changes in fair value that were attributable to both observable (e.g., changes in market interest rates) and unobservable (e.g., changes in unobservable long-dated volatilities) inputs. Warrant Liability Balance - January 1, 2014 $ 8,688 Additions during the period 20,992 Change in fair value 15,062 Balance – December 31, 2014 44,742 Change in fair value (15,676) Cashless warrants exercise (521) Warrants exercised for cash (264) Redeemable security settlement (299) Balance – December 31, 2015 $ 27,982 Date of valuation December 31, 2015 December 31, 2014 Strike price $ 3.49 $ 3.54 Contractual term (years) 3.1 4.1 Volatility (annual) 86.9 % 70.9 % Risk-free rate 1.3 % 1.8 % Dividend yield (per share) 0 % 0 % During fiscal 2015 approximately 184,000 Date of valuation 2015 Warrants Exercises Strike price $ 4.30 Contractual term (years) 2.1 Volatility (annual) 74.6 % Risk-free rate 0.5 % Dividend yield (per share) 0 % The development and determination of the unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company’s management.

Share-based Compensation

Share-based Compensation	12 Months Ended
	Dec. 31, 2015
Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	5. Share-based Compensation Compensation expense for all stock-based awards is measured on the grant date based on the fair value of the award and is recognized as an expense, on a straight-line basis, over the employee's requisite service period (generally the vesting period of the equity award). The fair value of each option award is estimated on the grant date using a Black-Scholes option valuation model. Stock-based compensation expense is recognized only for those awards that are expected to vest using an estimated forfeiture rate. The Company estimates pre-vesting option forfeitures at the time of grant and reflects the impact of estimated pre-vesting option forfeitures in compensation expense recognized. For options and warrants issued to non-employees, the Company recognizes stock compensation costs utilizing the fair value methodology over the related period of benefit. Related Party On January 17, 2014, in connection with the four Cognate BioServices Agreements, the Company issued one-time aggregate initiation payments of 5,101,366 2.0 8.7 The Company also entered into a Lock-Up Agreement with Cognate BioServices on January 17, 2014, under which Cognate BioServices agreed to have all of the shares that are issued as part of the Cognate BioServices Agreements (“Lock-Up Shares”) locked up for up to 36 months, in return for 15% warrant coverage for each 6-month period of lock-up, on the same terms as the warrants in the Cognate BioServices Agreements. During the lock-ups, the Lock-Up Shares may not be sold or traded on the market. These lock-up terms are subject to the same most favored nation treatment as provided in the Cognate BioServices Agreements. 2,325,467 5.0 4.00 3.08 2.92 Date of valuation July 17, 2014 December 31, 2015 Strike price $ 4.00 $ 3.35 Contractual term (years) 5.0 3.5 Volatility (annual) 78.2 % 86.9 % Risk-free rate 1.7 % 1.4 % Dividend yield (per share) 0 % 0 % The Company has evaluated the terms of the warrants with reference to the guidance provided in ASC 815-40-15. The Company has concluded that these warrants are not indexed to the Company’s own stock due to the most favored nation provision. Therefore, these warrants have been classified as a derivative liability as of July 17, 2014 and December 31, 2015. Stock based payment expense (restricted common stock and warrants) to Cognate for the ongoing vesting over 3 Cognate services was $ 2.0 8.7 for the years ended December 31, 2015 and 2014, respectively. Approximately $ 1.4 1 3.2 The Company issued 318,116 2.7 On October 19, 2015, the Company issued 8,052,092 On October 19, 2015, the Company issued 681,884 3.8 Other The Company issued 85,228 0.7

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	6. Property and Equipment December 31, December 31, 2015 2014 Leasehold improvements $ 69 $ 69 Office furniture and equipment 25 25 Computer equipment and software 598 137 Construction in progress (property in the United Kingdom) 45,681 39,928 46,373 40,159 Less: accumulated depreciation (216) (160) $ 46,157 $ 39,999 On August 19, 2014, the Company completed the first acquisition of a facility and property in the UK (“UK Facility”). The purchase price of the property was £ 13 20.8 2.6 25 The Company also capitalized a $ 6.2 On December 9, 2014, the Company completed the purchase of the second portion of the property intended for the manufacturing expansion for DCVax products in the UK. This property is located within and surrounded by the first portion of the property already acquired by the Company as previously reported. The purchase price for the additional property was £ 5 7.9 2.4 12 During the years ended December 31, 2015 and 2014, the Company capitalized $ 5.8 11.5 Depreciation expense was approximately $ 56,000 12,000

Notes Payable

Notes Payable	12 Months Ended
	Dec. 31, 2015
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	7. Notes Payable 2014 Convertible Senior Notes On August 19, 2014, the Company completed a private offering of $ 17.5 7.30 16.2 The Senior Notes are due on August 15, 2017, and are not convertible during the first three months, unless the current stock price is greater than 150% of the conversion price. Thereafter, the Senior Notes are convertible at any time 7.30 6.60 30 2.6 The Company has remaining $ 1.2 During the year ended December 31, 2015, $ 6.5 1,023,535 For the years ended December 31, 2015 2014 Contractual interest $ 640 $ 321 Accelerated interest due to the conversion of convertible senior notes into common stock 763 - Amortization of debt issuance costs 363 157 Accelerated amortization of debt issuance cost due to the conversion of convertible senior notes into common stock 302 - Total interest expense on the convertible senior notes $ 2,068 $ 478 Mortgage Loan On November 17, 2014, the Company entered into a bridge loan agreement (“the Mortgage”) with Lancashire Mortgage Corporation Limited in UK for approximately $ 10 6.25 2 12 7 4.5 0.3 On February 13, 2015, the Company entered into a mortgage loan agreement (the “Mortgage”) with Lancashire Mortgage Corporation Limited in the UK to expand the facility to $ 12 7.75 1.5 12 5 3.25 0.1 Interest expense related to the February 13, 2015 and November 17, 2014 mortgage loans amounted to approximately $ 2.0 0.2 1.4 0.1 12 0.6 0.1 Demand Loans On October 8, 2015, Leslie J. Goldman, an officer of the Company, loaned the Company $ 400,000 8 35 403,858 28,384 5 4.98 On October 22, 2015, Cognate loaned the Company $ 1,000,000 8 1,009,644 Other Notes Payable December 31, December 31, 2015 2014 Notes payable - current 12% unsecured originally due July 2011 - in dispute (1) $ 934 $ 934 934 934 Convertible notes payable, net - current 6% unsecured (2) 135 135 8% unsecured note due 2014 - 53 135 188 Note payable 6% due on demand (3) 50 50 50 50 Total notes payable, net $ 1,119 $ 1,172 (1) This $0.934 million note, which was originally due in July 2011 is currently under dispute with the creditor as to the validity of the note payable balance, which the Company believes has already been paid in full and is not outstanding. (2) This $0.135 million note as of December 31, 2015 consists of two separate 6 (3) This $0.050 million demand note as of December 31, 2015 is held by an officer of the Company. The holder has made no demand for payment, but reserves the right to make a demand at any time. For the year ended December 31, 2014, the Company converted notes and relevant accrued interest of $ 0.2 0.07 For the year ended December 31, 2014, the Company made a repayment of $ 0.02

Net Loss per Share Applicable t

Net Loss per Share Applicable to Common Stockholders	12 Months Ended
	Dec. 31, 2015
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	8. Net Loss per Share Applicable to Common Stockholders Options, warrants, and convertible debt outstanding were all considered anti-dilutive for the years ended December 31, 2015, 2014 and 2013, due to net losses. For the years ended December 31, 2015 2014 2013 Common stock options 1,551 1,551 1,551 Common stock warrants - equity treatment 14,834 16,830 15,321 Common stock warrants - liability treatment 12,433 12,555 2,233 Convertible notes and accrued interest 1,763 2,479 127 Potentially dilutive securities 30,581 33,415 19,232

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2015
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	9. Related Party Transactions a. Cognate BioServices The Company and Cognate BioServices entered into a DCVax-L Manufacturing Services Agreement and a DCVax-Direct Manufacturing Services Agreement, both effective January 17, 2014, and those Agreements followed and superseded Manufacturing Services Agreements in 2011 and 2007. The 2007 and 2011 Agreements had provided for baseline charges to the Company per month for dedicated manufacturing capacity, and the 2014 DCVax-L and DCVax-Direct Manufacturing Services Agreements also provide for such baseline charges. These minimum charges reflect the fact that the manufacturing suites and capacity that are going to be used for production of the Company’s DCVax products must be dedicated exclusively to the DCVax products and cannot be used to produce numerous different clients’ products in batches on a “campaign” basis, as is usually the case in contract manufacturing facilities. See description in Note 1 above. The capacity charges in the DCVax-L and DCVax-Direct Agreements entered into in January 2014 were increased in accordance with the expansion of DCVax-L and DCVax-Direct production needed for the Company’s growing programs and requested by the Company. The amount of production requested by the Company under the 2011 Agreement had greatly exceeded the maximum amount the Company had contracted for. The 2007 and 2011 Agreements also contained certain provisions for fees in the event that the Company shuts down or suspends its DCVax-L clinical trial program during the Term of the Agreement. Under the April 2011 Agreement, the Company was contingently obligated to pay a $ 2 Under the January 17, 2014 DCVax®-L Manufacturing Services Agreement and the DCVax-Direct Agreement, a new set of provisions apply going forward to any shut down or suspension. Under these provisions, the Company will be contingently obligated to pay certain fees to Cognate BioServices (in addition to any other remedies) if the Company shuts down or suspends its DCVax-L program or DCVax-Direct program. For a shut down or suspension of the DCVax-L program, the fees will be as fol l • Prior to the last dose of the last patient enrolled in the Phase III trial for DCVax®-L or After the last dose of the last patient enrolled in the Phase III clinical trial for DCVax®-L but before any submission for product approval in any jurisdiction or after the submission of any application for market authorization but prior to receiving a marketing authorization approval: in any of these cases, the fee shall be $ 3 • At any time after receiving the equivalent of a marketing authorization for DCVax®-L in any jurisdiction, the fee shall be $ 5 During 2014 and 2013, the Company paid a substantial portion of Cognate’s invoices in stock rather than cash. At December 31, 2015, 2014, the Company owed Cognate BioServices $ 5.5 5.7 During the years ended December 31, 2015, 2014 and 2013, the Company incurred non-cash equity based compensation (restricted common stock and warrants) related to Cognate BioServices of $ 40.8 21.3 2.3 The fair value calculation of these shares was determined using the market price for unrestricted tradable shares. However the shares issued to Cognate BioServices were unregistered nontradable shares, and were also subject to multiple additional restrictions including affiliate restrictions, a 3-year vesting period and a 3-year Lock-up. The equity compensation also included lock-up warrants (for the lock-up of Cognate shares) and most favored nation shares and warrants. The Company incurred research and development costs related to Cognate BioServices of $ 78.5 61.0 26.8 The Company issued 318,116 2.7 On October 19, 2015, the Company issued 8,052,092 38.8 On October 19, 2015, the Company also approved the issuance of 3,812,555 warrants which had been approved by the Board on November 12, 2014 and publicly reported by the Company at that time and thereafter. The 3,812,555 On October 22, 2015, the Company issued 681,884 3.8 Cognate BioServices Accounts Payable Conversions and Inducement Charge On July 31, 2013, Cognate BioServices, a related party supplier, agreed to convert an aggregate of $ 11.6 4.00 2.9 During the year ended December 31, 2014, $ 16.8 4.2 2.2 16.0 During the year ended December 31, 2013, $ 13.5 4.7 2.4 3 The conversion shares are subject to a Lock-up period of 36 Inducement expense is calculated based upon the difference between the carrying value of the accounts payable and the fair value of the restricted stock and warrants on the date such shares and warrants are issued. The Company classified the warrants as liabilities measured at fair value (with fair value determined as noted above), and re-measured the instruments at fair value each reporting period. Cognate BioServices’ cash purchase of common stock On June 30, 2014, Cognate BioServices purchased 562,500 281,250 from the Company f 2.3 The inducement charge was $ 2.4 Demand Note On October 22, 2015, Cognate loaned the Company $ 1,000,000 8 1,009,644 Short term loans In July 2013, Cognate provided $ 1.2 "Short swing" profit rules under Section 16(b) The Company and Cognate BioServices, an affiliate of the Company, conducted a review of the Company securities held by Cognate BioServices, the issuances to date, and any actions or transactions involving Company securities held by Cognate BioServices. In the course of the review, the parties noted that Cognate BioServices awarded some shares of Company stock that were owned by Cognate BioServices to two of Cognate BioServices’ managers, as part of the two managers’ compensation (the “Equity Awards”). The parties further noted that these Equity Awards may be deemed to be “dispositions” of those Company shares for purposes of Section 16(b) of the Securities Exchange Act of 1934 (“Section 16(b)”). Since the Equity Awards were made within six months of the time that various issuances of Company stock were made by the Company to Cognate BioServices in payment of accounts payable, as previously disclosed, the Equity Awards may be deemed to have resulted in “short swing” profits under Section 16(b). Also in the course of the review, the parties noted that Cognate BioServices had entered into two convertible debt financings with unrelated third party investors, secured by Cognate BioServices assets, and provided the proceeds of the financings for NWBO’s programs. The debt was convertible, at the investors’ election, into shares of Company stock owned by Cognate BioServices. The third party investors elected to convert the debt and receive repayment in shares of Company stock rather than in cash. In the review, the Company and Cognate BioServices noted that the debt conversions related to these two financings may be deemed to be “dispositions” of those Company shares for purposes of Section 16(b). Since the debt conversions by the third party investors were made within six months of the time that various issuances of Company stock were made by the Company to Cognate BioServices in payment of accounts payable, as previously disclosed, the debt conversions may be deemed to have resulted in “short swing” profits under Section 16(b). To resolve any uncertainty regarding whether these transactions constituted dispositions that were subject to Section 16(b), during the fourth quarter of 2014, Cognate BioServices agreed to pay the Company $ 0.448 In April, 2015, a purported shareholder filed a complaint against the Company and Cognate in the District Court for the Southern District of New York. The same plaintiff had previously filed such a complaint and then withdrew it to amend it. The complaint sought to force disgorgement of a larger amount, which the plaintiff alleged was unknown but was estimated to be approximately $ 1.4 On September 23, 2015, the parties entered a Stipulation of Settlement for expediency, and filed it with the Court. Under the terms of the Stipulation of Settlement, which is subject to the Court’s approval, the plaintiff shall dismiss the action with prejudice against Cognate and fully and finally release Cognate from all claims that were or could have been asserted in the action, and Cognate shall pay to the Company the amount of $ 500,000 125,000 On October 23, 2015, the plaintiff submitted to the Court an unopposed motion in support of the Stipulation of Settlement. On December 2, 2015, the Court approved the parties’ proposed settlement. b. Toucan Capital and Toucan Partners In March 2013, the Company received a short-term loan of $ 0.2 c. Other Related Parties In March 2013, the Company received a short-term loan of $ 0.2

Stockholders' Deficit

Stockholders' Deficit	12 Months Ended
	Dec. 31, 2015
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	10. Stockholders’ Deficit Common Stock Issuances First Quarter 2015 During the quarter ended March 31, 2015, the Company issued an aggregate of 888,187 3.7 During the quarter ended March 31, 2015, the Company issued 80,068 0.3 During the quarter ended March 31, 2015, the Company issued an aggregate of 385,000 0.5 Second Quarter 2015 On April 2, 2015, the Company entered into a stock purchase agreement (the “Agreement”) with Woodford Investment Management LLP as agent for the CF Woodford Equity Income Fund and other clients (collectively, “Woodford”). Pursuant to the Agreement, the Company agreed to sell, and Woodford agreed to purchase, 5,405,405 0.001 7.40 40 1,554,054 11.5 April 8, 2015 3,851,351 28.5 May 1, 2015 During the quarter ended June 30, 2015, the Company converted $ 4.5 701,033 During the quarter ended June 30, 2015, the Company issued an aggregate of 723,422 3.1 9,200 0.06 During the quarter ended June 30, 2015, the Company issued an aggregate of 183,895 During the quarter ended June 30, 2015, the Company issued an aggregate of 85,228 0.7 During the quarter ended June 30, 2015, the Company issued an aggregate of 318,116 8.1 were approved by the Company’s Board in November 2014, and publicly reported at that time and thereafter, . Third Quarter 2015 During the quarter ended September 30, 2015, the Company issued an aggregate of 116,675 0.8 57,500 0.2 During the quarter ended September 30, 2015, the Company issued an aggregate of 2,566 During the quarter ended September 30, 2015, the Company converted $ 2 322,502 Fourth Quarter 2015 Effective October 2015, the Company entered into a stock purchase agreement (the “Agreement”) with Woodford Investment Management LLP as agent for the CF Woodford Equity Income Fund and other clients (collectively, “Woodford”). Pursuant to the Agreement, the Company issued 5,454,545 0.001 5.50 30 Additionally, in connection with the Woodford Financing, the Company issued 681,884 which were supposed to be registered tradable shares on the same terms as the Shares issued to Woodford, to satisfy $ 3.8 . On October 19, 2015, the Company issued 8,052,092 and thereafter, but had not yet been issued while the parties were finalizing certain terms, 38.8 The fair value was determined based upon the market price of unrestricted tradable shares. On December 22, 2015, the Company entered into a Securities Purchase Agreement (the “Agreement”) with certain healthcare-focused institutional investors (the “Purchasers”), for a registered direct offering (the “Offering”) of 3,500,000 0.001 3.60 1,750,000 4.50 12.6 11.65 First Quarter 2014 During the quarter ended March 31, 2014, the Company issued in aggregate 238,496 1.6 On January 17, 2014, in connection with the four Cognate BioServices Agreements, the Company issued one-time initiation payments of 5,101,366 8.7 . During the quarter ended March 31, 2014, the Company issued in aggregate 32,000 0.2 During the quarter ended March 31, 2014, the Company converted accounts payable due to Cognate BioServices of approximately $ 5.9 1,481,644 2.8 2.5 5.3 During the quarter ended March 31, 2014, the Company converted notes and relevant accrued interest of $ 0.2 0.07 During the quarter ended March 31, 2014, the Company issued an aggregate of 721,827 2.7 During the quarter ended March 31, 2014, 1,444,788 8.9 During the quarter ended March 31, 2014, the Company issued an aggregate of 41,310 During the quarter ended March 31, 2014, the Company issued 20,833 0.1 Second Quarter 2014 On April 9, 2014, the Company entered into a Securities Purchase Agreement with a single institutional investor for the sale of 2,272,727 6.60 15.0 2,272,727 7.50 17.05 On June 30, 2014, the Company issued Cognate BioServices 562,500 281,250 2.3 million. The shares and warrants are subject to most favored nation treatment with respect to the terms (including in regard to warrants) provided to any other investors or creditors, including share issuances upon the exercise of previously issued derivative securities. During the quarter ended June 30, 2014, the Company issued 200,000 7.00 1.4 1.4 During the quarter ended June 30, 2014, the Company issued 58,614 435,540 During the quarter ended June 30, 2014, the Company issued 16,200 125,550 During the quarter ended June 30, 2014, the Company issued an aggregate of 92,100 During the quarter ended June 30, 2014, the Company issued an aggregate of 12,533 During the quarter ended June 30, 2014, the Company issued an aggregate of 24,924 155,607 During the quarter ended June 30, 2014, the Company converted accounts payable due to Cognate BioServices of approximately $ 2.9 727,291 363,646 1.4 1.1 2.5 Third Quarter 2014 During the quarter ended September 30, 2014, the Company entered into a Securities Purchase Agreement with an individual investor for the sale of 435,202 5.17 448,207 5.02 4.5 1,398,625 During the quarter ended September 30, 2014, the Company issued an aggregate of 497,133 1.7 During the quarter ended September 30, 2014, the Company converted accounts payable due to Cognate BioServices of approximately $ 7.9 1,986,205 1.1 4.5 3.8 8.3 During the quarter ended September 30, 2014, the Company issued an aggregate of 14,519 94,999 On August 12, 2014, the Company issued 3,013 5.60 1,507 15,000 On September 19, 2014, the Company issued 49,107 5.60 14,732 275,000 During the quarter ended September 30, 2014, the Company issued 52,120 0.3 Fourth Quarter 2014 On October 6, 2014, the Company entered into a Stock Purchase, Amendment and Issuance Agreement (the “Agreement”) with an existing single institutional investor for the sale of 2,272,727 5.05 11.5 2,272,727 7.50 2,735,000 5.15 During the quarter ended December 31, 2014, the Company issued 109,868 0.4 On November 17, 2014, the Company entered into a private offering of $ 25 4,317,789 5.79 During the quarter ended December 31, 2014, the Company entered into a service agreement with an agent for services provided on the UK mortgages. On November 19, 2014, the Company issued total 38,400 5.15 197,376 First Quarter 2013 During the quarter ended March 31, 2013, the Company issued 235,593 0.9 For the quarter ended March 31, 2013, the Company converted $ 0.9 359,000 2.60 Second Quarter 2013 During the quarter ended June 30, 2013, the Company issued a total of 178,504 0.6 In April 2013, the Company entered into an agreement with an institutional investor for $ 1.0 281,690 3.55 In April 2013, the Company entered into an agreement with one healthcare-dedicated institutional investor for a registered direct placement of $ 10.0 3.90 2,564,103 1,025,641 4.29 0.8 During the quarter ended June 30, 2013, the Company converted $ 0.9 316,000 2.90 During the quarter ended June 30, 2013, the Company issued an aggregate of 168,354 Third Quarter 2013 During the quarter ended September 30, 2013, the Company issued an aggregate of 14,326 0.1 During the third quarter of 2013, the Company entered into a series of extension agreements, with a counterparty owning 366,667 30,000 3.46 On August 8, 2013, the Company entered into a securities purchase agreement with institutional investors for the sale of an aggregate of $ 15.0 4,477,612 1,119,403 4.00 3.35 1.2 During the third quarter ended September 30, 2013, the Company converted $ 10.3 2,902,072 3.55 During the third quarter ended September 30, 2013, the Company converted $ 0.5 184,600 2.60 164,155 Fourth Quarter 2013 During the quarter ended December 31, 2013 the Company issued in aggregate 141,330 0.7 During the quarter ended December 31, 2013, the Company issued an aggregate of 733,104 3.68 2.7 During the fourth quarter of 2013, the Company redeemed 41,667 0.2 During the fourth quarter of 2013, 383,315 1.9 During the quarter ended December 31, 2013, the Company issued an aggregate of 179,094 0.6 In November 2013, the Company entered into an underwriting agreement for a registered direct placement of $ 27.0 4.80 5,630,208 4.80 27.0 2,815,104 6.00 2.0 25.0 6.00 5.6 During the quarter ended December 31, 2013, the Company converted accounts payable to Cognate BioServices into approximately 1,818,000 150,000 6.7 0.5 1.5 During the quarter ended December 31, 2013, the Company converted $ 0.5 149,732 Stock Purchase Warrants Number of Weighted Average Warrants Exercise Price Outstanding as of January 1, 2013 12,086 $ 6.18 Warrants issued for services 183 5.83 Warrants issued in connection with April 2013 registered direct offering 1,026 4.29 Warrants issued in connection with August 2013 registered direct offering 2,239 4.00 Warrants issued in connection with October 2013 registered direct offering 2,815 6.00 Warrants issued to placement agent in connection with April 2013 registered direct offering 128 4.29 Warrants issued in connection with conversion of Cognate accounts payable* 2,356 4.00 Warrants issued for extension of redeemable securities 126 5.01 Warrants exercised for cash (179) 3.35 Warrants exercised on a cashless basis (168) 5.60 Warrants expired and cancellation (496) 12.07 Outstanding as of December 31, 2013 20,116 5.23 Warrants issued in connection with conversion of Cognate accounts payable* 2,226 4.00 Warrants issued to Cognate for services* 4,760 4.00 Warrants issued for services 17 6.33 Warrants issued in connection with common stock issued 150 5.00 Warrants exercised on a cashless basis (73) - Warrants exercised for cash (1,309) 3.63 Warrants issued to Cognate in connection with common stock issued for cash* 281 4.00 Over-allotment rights issued in connection with registered direct offering 2,273 7.50 Warrants issued to placement agent in connection with registered direct offering 113 8.25 Warrants issued in connection with registered direct offering 2,735 5.15 Warrants canceled (2,273) 7.50 Warrants adjustment for prior period 419 6.43 Expired and canceled in fourth quarter 2014 (50) 8.29 Outstanding as of December 31, 2014 29,385 4.72 Warrants granted 1,953 4.51 Warrants exercised for cash (1,678) 4.25 Warrants exercised on a cashless basis* (304) 3.96 Warrant adjustment due to Cognate price reset 62 3.35 Warrants expired and cancellation (2,431) 4.82 Adjustment related to prior issued warrants 280 4.41 Outstanding as of December 31, 2015 ** 27,267 $ 4.40 *The warrants contain “down round protection” and the Company classifies these warrant instruments as liabilities at their fair value and adjusts the instruments to fair value at each reporting period. ** Approximately 14,323,003 3.3 4.0

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	11. Commitments and Contingencies On July 31, 2012, the Company entered into a non-cancelable operating lease for 7,097 square feet of office space in Bethesda, Maryland, which expires in March 2018. Rent expense for 2015 and 2014 amounted to $ 0.3 0.3 On October 28, 2013, the Company entered into a non-cancelable operating lease for 4,251 square feet of office space in Germany, which expires in December 2017. Office Leases Germany U.S. 2016 $ 67 $ 309 2017 67 318 2018 - 81 Total $ 134 $ 708 Derivative and Class Action Litigation In 2014, as previously reported, the Company received demand letters from three purported individual shareholders seeking to inspect our corporate books and records pursuant to Section 220 of the Delaware General Corporation Law. The demand letters were all substantially similar, and claimed that their purpose is to investigate possible mismanagement and breaches of fiduciary duty by the Company’s directors and officers. They requested a range of documents. On November 13, 2014, one of the purported shareholders filed a complaint in the Delaware Court of Chancery seeking to enforce her books and records demand. The Company reached negotiated agreements and provided limited records, under confidentiality agreements. On July 16, 2015, the parties filed, and the court entered, a stipulation dismissing the case. On June 19, 2015, two of the purported shareholders filed a complaint purportedly suing on behalf of a class of similarly situated shareholders and derivatively on behalf of the Company in the Delaware Court of Chancery. The lawsuit names Cognate BioServices, Inc., Toucan Partners, Toucan Capital Fund III, our CEO Linda Powers and the Company’s Board of Directors as defendants, and names the Company as a “nominal defendant” with respect to the derivative claims. The complaint generally objects to certain transactions between the Company and Cognate and the Toucan entities, in which Cognate and the Toucan entities provided services and financing to the Company, or agreed to conversion of debts owed to them by the Company into equity. The complaint seeks unspecified monetary relief for the Company and the plaintiffs, and various forms of equitable relief, including disgorgement of allegedly improper benefits, rescission of the challenged transactions, and an order forbidding similar transactions in the future. On September 1, 2015, the Company and other named defendants filed motions to dismiss. In response, the plaintiffs filed an amended complaint on November 6, 2015. The Company and the other named defendants filed motions to dismiss plaintiffs’ amended complaint on January 19, 2016. The Company intends to continue to vigorously defend the case. On November 19, 2015, a third purported shareholder who had sought corporate books and records filed a complaint in the U.S. District Court for the District of Maryland, claiming to sue derivatively on behalf of the Company. The complaint names the Company’s Board of Directors, Toucan Capital Fund III, L.P., Toucan General II, LLC, Toucan Partners, LLC, and Cognate as defendants, and names the Company as a nominal defendant. The complaint claims that the plaintiff made a demand on the Company’s Board of Directors to commence an action against the Company’s directors and its CEO and that the plaintiff commenced the derivative action after not receiving a response to the demand letter within an allegedly “sufficient time.” The complaint further claims that the Company purportedly overcompensated Cognate and Toucan for certain services and loans in payments of stock, and that the Company’s CEO, Ms. Powers, benefited from these transactions with Cognate and Toucan, which she allegedly owns or controls. The complaint asserts that the alleged overpayments unjustly enriched Ms. Powers, Toucan, and Cognate. The Complaint also claims that the Company’s directors breached their fiduciary duties of loyalty and good faith to the Company by authorizing the payments to Cognate. Finally, the complaint claims that Ms. Powers, Cognate, and Toucan aided and abetted the directors’ breaches of fiduciary duties by causing the board to enter into the agreements with Cognate. The plaintiff seeks an award of unspecified damages to the Company and seeks equitable remedies, including disgorgement by Ms. Powers, Toucan, and Cognate of the allegedly improper benefits received as a result of the disputed transactions. The plaintiff also seeks costs and disbursements associated with bringing suit, including attorneys’ fees and expert fees. On February 2, 2016, plaintiff and defendants filed a joint motion to stay the proceedings pending an investigation by a special committee of the Company’s Board of Directors into the allegations asserted in the demand letter and underlying the lawsuit. The Company intends to vigorously defend this case. Class Action Securities Litigation On August 26, 2015, a purported shareholder of the Company filed a putative class action complaint in the U.S. District Court for the District of Maryland. The lawsuit names the Company and Ms. Powers as defendants. On December 14, 2015, the court appointed two lead plaintiffs. The Lead Plaintiffs filed an amended complaint on February 12, 2016, purportedly on behalf of all of those who purchased common stock in NW Bio between January 13, 2014 and August 21, 2015. The amended complaint generally claims that the defendants violated Section 10(b) and Section 20(a) of the Securities Exchange Act of 1934 by making misleading statements and/or omissions on a variety of subjects, including the status and results of the Company’s DCVax trials. The amended complaint seeks unspecified damages, attorneys’ fees, and costs. The Company intends to vigorously defend the case. Shareholder Books and Record Demand On December 7, 2015, the Company received a letter on behalf of certain Section 16 Matters As previously reported, the Company previously received demand letters from two purported individual shareholders alleging “short swing” profits under Section 16(b) of the Exchange Act arising from Cognate awarding to some of its own employees some of the Company shares that Cognate owned, and arising from a convertible debt financing transaction in which the unrelated investor chose to convert the debt into shares of the Company stock owned by Cognate rather than being repaid in cash. However, prior to either of these demand letters, the Company had already filed a Form 8-K on December 19, 2014, in which it already disclosed this same information (which had been found in the course of a joint review by Cognate and the Company), already agreed with Cognate on the disgorgement of those deemed profits ($448,681) by Cognate and resolved the matter. The Company believes that the payment by Cognate fully resolved the matters, and so informed the purported shareholders who sent the demand letters. In April, 2015, one of those purported individual shareholders filed a complaint against the Company and Cognate in the District Court for the Southern District of New York. The same plaintiff had previously filed such a complaint and then withdrew it to amend it. The complaint sought to force disgorgement of a larger amount, which the plaintiff alleged was unknown but was estimated to be approximately $ 1.4 On September 23, 2015, the parties entered a Stipulation of Settlement for expediency, and filed it with the Court. Under the terms of the Stipulation of Settlement, which is subject to the Court’s approval, the plaintiff shall dismiss the action with prejudice against Cognate and fully and finally release Cognate from all claims that were or could have been asserted in the action, and Cognate shall pay to the Company the amount of $ 500,000 125,000 125,000 500,000 On October 23, 2015, the plaintiff submitted to the Court an unopposed motion in support of the Stipulation of Settlement. On December 2, 2015, the Court approved the parties’ proposed settlement.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	12. Income Taxes There was no income tax benefit attributable to net losses for 2015 and 2014. The difference between actual tax provisions and taxes computed by applying the corporate rate of 39.4 As of As of December 31, 2015 December 31, 2014 Deferred tax asset Net operating loss carryforward $ 180,927 $ 133,684 Research and development credit carry forwards 12,661 $ 9,911 Stock based compensation and other 24,759 26,510 Total deferred tax assets 218,347 170,105 Valuation Allowance (218,347) (170,105) Deferred tax asset, net of allowance $ - $ - The Company has identified the United States and Maryland, as significant tax jurisdiction. At December 31, 2015, the Company had net operating loss carry forwards for income tax purposes of approximately $ 458.7 12.7 During 2015 the company reevaluated the pricing/deductibility of stock options granted and the value of warrants issued, resulting in the decrease in the potential future tax deduction from those instruments. During 2015 the company has adjusted/reevaluated its R&D credit calculations, resulting in the decrease in the possible future credit against tax of $ 1.6 In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and taxing strategies in making this assessment. In case the deferred tax assets will not be realized in future periods, the Company has provided a valuation allowance for the full amount of the deferred tax assets at December 31, 2015 and 2014. (dollars in thousands) For year ended For year ended December 31, 2015 December 31, 2014 Statutory federal income tax rate 34.0 % 34.0 % State taxes, net of federal tax benefit 5.4 % 5.4 % Other, net 5.8 % -0.4 % Research and development credits 2.6 % 4.4 % Change in valuation allowance -47.8 % -43.4 % Income tax provision (benefit) 0.0 % 0.0 % For year ended For year ended December 31, 2015 December 31, 2014 Federal Current $ - $ - Deferred 41,583 49,912 State Current - - Deferred 6,659 7,993 Change in valuation allowance (48,242) (57,905) Income tax provision (benefit) $ - $ -

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2015
Subsequent Events [Abstract]
Subsequent Events [Text Block]	13. Subsequent Events The Company has evaluated all events that occur after the balance sheet date through the date when the financial statements were issued to determine if they must be reported. The Management of the Company determined that there were reportable subsequent events to be disclosed. Equity Financing On February 29, 2016, the Company entered into a Securities Purchase Agreement (the “Agreement”) with certain institutional investors (the “Purchasers”), for a registered direct offering (the “Offering”) of 5,882,353 1.70 2,941,177 2.25 In addition, the Company granted the Purchasers a sixty (60) day overallotment option in the form of Series B Warrants to purchase an additional 5,882,353 3.00 10 9,210,000 In a concurrent private placement, each Purchaser will also receive Series C Warrants (the “Series C Warrants”) to purchase up to 2,941,177 4.00

Selected Quarterly Financial Da

Selected Quarterly Financial Data	12 Months Ended
	Dec. 31, 2015
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Information [Text Block]	14. Selected Quarterly Financial Data (Unaudited) First Second Third Fourth (in thousands, except per share data) Quarter Quarter Quarter Quarter 2015 Research grant and other $ 194 $ 391 $ 291 $ 863 Operating expenses $ 23,025 $ 39,245 $ 13,504 $ 52,249 Other income/(expense) $ (23,602) $ (27,991) $ 35,828 $ 27,308 Net (loss)/income $ (46,433) $ (66,845) $ 22,615 $ (24,078) Basic net (loss)/income per common share $ (0.67) $ (0.88) $ 0.29 $ (0.27) Diluted net (loss)/income per common share $ (0.67) $ (0.88) $ 0.25 $ (0.27) 2014 Research grant and other $ - $ - $ 582 $ 872 Operating expenses $ 23,682 $ 25,427 $ 27,190 $ 26,298 Other income/(expense) $ (22,359) $ (438) $ 5,565 $ (17,259) Net loss $ (46,041) $ (25,865) $ (21,043) $ (42,685) Basic and diluted net loss per common share $ (0.88) $ (0.45) $ (0.35) $ (0.64)

Summary of Significant Accoun22

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The accompanying consolidated financial statements of the Company were prepared in accordance with generally accepted accounting principles in the U.S. (“U.S. GAAP”) and include the assets, liabilities, revenues and expenses of the wholly owned subsidiaries in Germany, Switzerland and the United Kingdom. All intercompany transactions and accounts have been eliminated in consolidation.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents Cash consists of funds deposited in checking accounts. While cash held by financial institutions may at times exceed federally insured limits, management believes that no material credit or market risk exposure exists due to the high credit quality of the institutions that have custody of the Company’s funds. The Company has not incurred any losses on such accounts.
Property, Plant and Equipment, Policy [Policy Text Block]	Property, Plant and Equipment Property and equipment are stated at cost. Depreciation and amortization are provided for using straight-line methods, in amounts sufficient to charge the cost of depreciable assets to operations over their estimated service lives. The UK Property’s building will be depreciated over 15
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments The fair value of financial instruments other than liabilities payable to related parties approximate the recorded value based on the short term nature of these financial instruments. The fair value of derivative liabilities is measured using a binomial model or Monte Carlo simulation depending on the complexity of the derivative (Note 4).
Deferred Charges, Policy [Policy Text Block]	Deferred Financing Costs The Company capitalizes costs related to the issuance of debt which are included on the accompanying consolidated balance sheets. Deferred financing costs are amortized using a method that approximates the interest method over the life of the related loan and are included as a component of interest expense on the accompanying consolidated statements of operations. As of December 31, 2015, deferred financing costs were $ 0.9 1.2
Warrant Liability Policy [Policy Text Block]	Warrant Liability The Company accounts for the 12,433,310
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Impairment of Long-Lived Assets The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. In performing a review for impairment, the Company compares the carrying value of the assets with its estimated future undiscounted cash flows from the use of the asset and eventual disposition. If the estimated undiscounted future cash flows are less than carrying value, an impairment loss is charged to operations based on the difference between the carrying amount and the fair value of the asset.
Environmental Cost, Expense Policy [Policy Text Block]	Environmental Remediation Liabilities The Company records environmental remediation liabilities for properties acquired. The environmental remediation liabilities are initially recorded at fair value. The liability is reduced for actual costs incurred in connection with the clean-up activities for each property. Upon completion of the clean-up, the environmental remediation liability is adjusted to equal the fair value of the remaining operation, maintenance and monitoring activities to be performed for the property. The reduction in the liability resulting from the completion of the clean-up is included in other income. As of December 31, 2015, we estimate that the total environmental remediation costs associated with the purchase of the UK Facility will amount to approximately $ 6.2 $ 6.2 $ 4.5 $ 32.0
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency Translation and Transactions The Company has operations in Germany, the United Kingdom and Canada, in addition to the U.S. Assets and liabilities are translated into U.S. dollars using end of period exchange rates and revenues and expenses are translated into U.S. dollars using weighted average rates. Foreign currency translation adjustments are reported as a separate component of accumulated other comprehensive income (loss) within stockholders’ equity (deficit). During the year ended December 31, 2015, the Company recorded $ 67 Foreign currency transaction gains and losses are recognized in the Consolidated Statements of Operations as incurred.
Comprehensive Loss Policy [Policy Text Block]	Comprehensive Loss The Company reports comprehensive loss and its components in its consolidated financial statements. Comprehensive loss consists of net loss and foreign currency translation adjustments, affecting stockholders’ equity (deficit) that, under U.S, GAAP, is excluded from net loss.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition The Company recognizes revenue in accordance with the terms stipulated under the patient service contract. In various situations, the Company receives certain payments for DCVax®-L for patient treatment. These payments are non-refundable, and are not dependent on the Company’s ongoing future performance. The Company has adopted a policy of recognizing these payments as revenue when received.
Accrued Outsourcing Costs [Policy Text Block]	Substantial portions of our preclinical studies and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors (collectively "CROs"). These CROs generally bill monthly or quarterly for services performed, or bill based upon milestones achieved. For clinical studies, expenses are accrued based upon the number of patients enrolled and the duration of the study. The Company monitors patient enrollment, the progress of clinical studies and related activities through internal reviews of data that is tracked by the CROs under contractual arrangements, correspondence with the CROs and visits to clinical sites.
Research and Development Expense, Policy [Policy Text Block]	Research and Development Costs Research and development costs are charged to operations as incurred and consist primarily of clinical trial costs, related party manufacturing costs, consulting costs, contract research and development costs, and compensation costs. For the years ended December 31, 2015, 2014 and 2013, the Company recognized research and development costs of $ 103.1 85.6 43.9 During 2014 and 2013, the Company paid a substantial portion of Cognate’s invoices in stock rather than in cash; during 2015, the Company mostly paid Cognate’s invoices in cash. At December 31, 2015 and 2014, the Company owed Cognate BioServices $ 5.5 5.7 During the years ended December 31, 2015, 2014 and 2013, the Company incurred non-cash equity based compensation (restricted common stock and warrants) related to Cognate BioServices of $ 40.8 million, $ 21.3 0 The Company incurred research and development costs related to Cognate BioServices of $ 78.5 61.0 26.8
Income Tax, Policy [Policy Text Block]	Income Taxes The Company recognizes income taxes on an accrual basis based on tax positions taken or expected to be taken in its tax returns. A tax position is defined as a position in a previously filed tax return or a position expected to be taken in a future tax filing that is reflected in measuring current or deferred income tax assets and liabilities. Tax positions are recognized only when it is more likely than not (i.e., likelihood of greater than 50%), based on technical merits, that the position would be sustained upon examination by taxing authorities. Tax positions that meet the more likely than not threshold are measured using a probability-weighted approach as the largest amount of tax benefit that is greater than 50% likely of being realized upon settlement. Income taxes are accounted for using an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in our financial statements or tax returns. A valuation allowance is established to reduce deferred tax assets if all, or some portion, of such assets will more than likely not be realized. Should they occur, our policy is to classify interest and penalties related to tax positions as income tax expense. Since our inception, no such interest or penalties have been incurred, however prior to 1998 the Company was a limited liability company and the Company’s tax losses and credits generally flowed directly to the members.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Non-Employee Stock Based Compensation The Company accounts for stock based compensation awards issued to non-employees for services, as prescribed by ASC 505, at either the fair value of the services or the instruments issued in exchange for such services (based on the same methodology described for employee stock based compensation), whichever is more readily determinable. Subsequent to the measurement date, the Company recognizes and classifies any future changes in the fair value in accordance with the relevant accounting literature on financial instruments ASC 815-40.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates In preparing financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. These estimates and assumptions include valuing equity securities in share-based payment arrangements, estimating the fair value of equity instruments recorded as derivative liabilities, useful lives of depreciable assets and whether impairment charges may apply, and the fair value of environmental remediation liabilities.
Earnings Per Share, Policy [Policy Text Block]	Loss per Share Basic loss per share is computed on the basis of the weighted average number of shares outstanding for the reporting period. Diluted loss per share is computed on the basis of the weighted average number of common shares (including redeemable shares) plus dilutive potential common shares outstanding using the treasury stock method. Any potentially dilutive securities are anti-dilutive due to the Company’s net losses. For the years presented, there is no difference between the basic and diluted net loss per share.
Operating Segments [Policy Text Block]	Segments The Company operates in one reportable segment and, accordingly, no segment disclosures have been presented herein.
Subsequent Events, Policy [Policy Text Block]	Subsequent Events The Company follows the provisions of ASC Topic 855-10, “Subsequent Events,” relating to subsequent events. This guidance establishes principles and requirements for subsequent events. This guidance defines the period after the balance sheet date during which events or transactions that may occur would be required to be disclosed in a company’s financial statements. The Company has evaluated subsequent events up to the date of filing of its Annual Report on Form 10-K for the year ended December 31, 2015 (see Note (13).
Significant Accounting Policies [Policy Text Block]	Adoption of Recent Accounting Pronouncements In August 2015, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2015-15, “Interest - Imputation of Interest: Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements”, which clarifies the treatment of debt issuance costs from line-of-credit arrangements after the adoption of ASU No. 2015-03, “Interest - Imputation of Interest: Simplifying the Presentation of Debt Issuance Costs”. In particular, ASU No. 2015-15 clarifies that the SEC staff would not object to an entity deferring and presenting debt issuance costs related to a line-of-credit arrangement as an asset and subsequently amortizing the deferred debt issuance costs ratably over the term of such arrangement, regardless of whether there are any outstanding borrowings on the line-of-credit arrangement. The Company adopted ASU No. 2015-15 during the first quarter of fiscal 2016, and its adoption did not have a material impact on its condensed financial statements.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers”, an updated standard on revenue recognition. ASU No. 2014-09 provides enhancements to the quality and consistency of how revenue is reported by companies while also improving comparability in the financial statements of companies reporting using International Financial Reporting Standards or U.S. GAAP. The main purpose of the new standard is for companies to recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration to which a company expects to be entitled in exchange for those goods or services. The new standard also will result in enhanced disclosures about revenue, provide guidance for transactions that were not previously addressed comprehensively and improve guidance for multiple-element arrangements. In July 2015, the FASB voted to approve a one-year deferral of the effective date of ASU No. 2014-09, which will be effective for the Company in the first quarter of fiscal year 2018 and may be applied on a full retrospective or modified retrospective approach. The Company is evaluating the impact of implementation and transition approach of this standard on its financial statements. In August 2014, the FASB issued ASU No. 2014-15, “Presentation of Financial Statements-Going Concern”, which defines management's responsibility to assess an entity's ability to continue as a going concern, and requires related footnote disclosures if there is substantial doubt about its ability to continue as a going concern. ASU No. 2014-15 is effective for the Company for the fiscal year ending on December 31, 2016, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU No. 2014-15 and its related disclosures. In November 2015, FASB issued ASU No. 2015-17, “Balance Sheet Classification of Deferred Taxes”. ASU No. 2015-17 requires that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. ASU No. 2015-17 is effective for financial statements issued for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. The Company is currently evaluating the impact that ASU No. 2015-17 will have on its balance sheet and financial statement disclosures. In January 2016, FASB issued ASU No. 2016-01, “Recognition and Measurement of Financial Assets and Financial Liabilities”. ASU No. 2016-01 requires equity investments to be measured at fair value with changes in fair value recognized in net income; simplifies the impairment assessment of equity investments without readily determinable fair values by requiring a qualitative assessment to identify impairment; eliminates the requirement for public business entities to disclose the method(s) and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost on the balance sheet; requires public business entities to use the exit price notion when measuring the fair value of financial instruments for disclosure purposes; requires an entity to present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting from a change in the instrument-specific credit risk when the entity has elected to measure the liability at fair value in accordance with the fair value option for financial instruments; requires separate presentation of financial assets and financial liabilities by measurement category and form of financial assets on the balance sheet or the accompanying notes to the financial statements and clarifies that an entity should evaluate the need for a valuation allowance on a deferred tax asset related to available-for-sale securities in combination with the entity’s other deferred tax assets. ASU No. 2016-01 is effective for financial statements issued for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The Company is currently evaluating the impact that ASU No. 2016-01 will have on its financial statements and related disclosures. On February 25, 2016, FASB issued its new lease accounting guidance in Accounting Standards Update (ASU) No. 2016-02, Leases (Topic 842). Under the new guidance, lessees will be required to recognize for all leases (with the exception of short-term leases) a lease liability, which is a lessee‘s obligation to make lease payments arising from a lease, measured on a discounted basis and a right-of-use asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset for the lease term. The new standard is effective for fiscal year beginning after December 15, 2018, including interim periods within those fiscal years (i.e. a January 1, 2019 effective date). The Company is currently evaluating the effect the guidance will have on its consolidated financial statements.

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	The following table presents information about the Company’s liabilities measured at fair value on a recurring basis and the Company’s estimated level within the fair value hierarchy of those liabilities as of December 31, 2015 and December 31, 2014 (in thousands): Fair value measured at December 31, 2015 Quoted prices in active Significant other Significant Fair value at markets observable inputs unobservable inputs December 31, 2015 (Level 1) (Level 2) (Level 3) Derivative liability $ 27,982 $ - $ - $ 27,982 Fair value measured at December 31, 2014 Quoted prices in active Significant other Significant Fair value at markets observable inputs unobservable inputs December 31, 2014 (Level 1) (Level 2) (Level 3) Derivative liability $ 44,742 $ - $ - $ 44,742
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Changes in Level 3 liabilities measured at fair value for the period ended December 31, 2015 and December 31, 2014 were as follows (dollars in thousands): Warrant Liability Balance - January 1, 2014 $ 8,688 Additions during the period 20,992 Change in fair value 15,062 Balance – December 31, 2014 44,742 Change in fair value (15,676) Cashless warrants exercise (521) Warrants exercised for cash (264) Redeemable security settlement (299) Balance – December 31, 2015 $ 27,982
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]	The Company’s warrant liabilities are measured at fair value using the Monte Carlo simulation valuation methodology. A summary of weighted average (in aggregate) about significant unobservable inputs (Level 3 inputs) used in measuring the Company’s warrant liabilities that are categorized within Level 3 of the fair value hierarchy for the years ended December 31, 2015 and 2014 is as follows: Date of valuation December 31, 2015 December 31, 2014 Strike price $ 3.49 $ 3.54 Contractual term (years) 3.1 4.1 Volatility (annual) 86.9 % 70.9 % Risk-free rate 1.3 % 1.8 % Dividend yield (per share) 0 % 0 %
Warrant [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]	The warrants were marked to market through other income (expense) and the balances were reclassified as stockholder’ equity (deficit) at the point of exercise. A summary of weighted average (in aggregate) significant unobservable inputs (Level 3 inputs) used in measuring warrant exercises for the year ended December 31, 2015 is as follows: Date of valuation 2015 Warrants Exercises Strike price $ 4.30 Contractual term (years) 2.1 Volatility (annual) 74.6 % Risk-free rate 0.5 % Dividend yield (per share) 0 %

Share-based Compensation (Table

Share-based Compensation (Tables)	12 Months Ended
	Dec. 31, 2015
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	The fair value of the warrants granted is based on the Monte Carlo simulation model using the following assumptions: Date of valuation July 17, 2014 December 31, 2015 Strike price $ 4.00 $ 3.35 Contractual term (years) 5.0 3.5 Volatility (annual) 78.2 % 86.9 % Risk-free rate 1.7 % 1.4 % Dividend yield (per share) 0 % 0 %

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	Property and equipment consist of the following at December 31, 2015 and December 31, 2014 (in thousands): December 31, December 31, 2015 2014 Leasehold improvements $ 69 $ 69 Office furniture and equipment 25 25 Computer equipment and software 598 137 Construction in progress (property in the United Kingdom) 45,681 39,928 46,373 40,159 Less: accumulated depreciation (216) (160) $ 46,157 $ 39,999

Notes Payable (Tables)

Notes Payable (Tables)	12 Months Ended
	Dec. 31, 2015
Debt Disclosure [Abstract]
Interest Income and Interest Expense Disclosure [Table Text Block]	The following table shows the details of interest expense related to 2014 Convertible Senior Notes for the years ended December 31, 2015 and 2014 (in thousands): For the years ended December 31, 2015 2014 Contractual interest $ 640 $ 321 Accelerated interest due to the conversion of convertible senior notes into common stock 763 - Amortization of debt issuance costs 363 157 Accelerated amortization of debt issuance cost due to the conversion of convertible senior notes into common stock 302 - Total interest expense on the convertible senior notes $ 2,068 $ 478
Schedule of Debt [Table Text Block]	December 31, December 31, 2015 2014 Notes payable - current 12% unsecured originally due July 2011 - in dispute (1) $ 934 $ 934 934 934 Convertible notes payable, net - current 6% unsecured (2) 135 135 8% unsecured note due 2014 - 53 135 188 Note payable 6% due on demand (3) 50 50 50 50 Total notes payable, net $ 1,119 $ 1,172 (1) This $0.934 million note, which was originally due in July 2011 is currently under dispute with the creditor as to the validity of the note payable balance, which the Company believes has already been paid in full and is not outstanding. (2) This $0.135 million note as of December 31, 2015 consists of two separate 6 (3) This $0.050 million demand note as of December 31, 2015 is held by an officer of the Company. The holder has made no demand for payment, but reserves the right to make a demand at any time.

Net Loss per Share Applicable27

Net Loss per Share Applicable to Common Stockholders (Tables)	12 Months Ended
	Dec. 31, 2015
Earnings Per Share [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	The following securities were not included in the diluted net loss per share calculation because their effect was anti-dilutive as of the periods presented (in thousands): For the years ended December 31, 2015 2014 2013 Common stock options 1,551 1,551 1,551 Common stock warrants - equity treatment 14,834 16,830 15,321 Common stock warrants - liability treatment 12,433 12,555 2,233 Convertible notes and accrued interest 1,763 2,479 127 Potentially dilutive securities 30,581 33,415 19,232

Stockholders' Deficit (Tables)

Stockholders' Deficit (Tables)	12 Months Ended
	Dec. 31, 2015
Stockholders' Equity Note [Abstract]
Schedule Of Warrant Activity [Table Text Block]	The following is a summary of warrant activity for the year ended December 31, 2015, 2014 and 2013 (dollars in thousands, except per share data): Number of Weighted Average Warrants Exercise Price Outstanding as of January 1, 2013 12,086 $ 6.18 Warrants issued for services 183 5.83 Warrants issued in connection with April 2013 registered direct offering 1,026 4.29 Warrants issued in connection with August 2013 registered direct offering 2,239 4.00 Warrants issued in connection with October 2013 registered direct offering 2,815 6.00 Warrants issued to placement agent in connection with April 2013 registered direct offering 128 4.29 Warrants issued in connection with conversion of Cognate accounts payable* 2,356 4.00 Warrants issued for extension of redeemable securities 126 5.01 Warrants exercised for cash (179) 3.35 Warrants exercised on a cashless basis (168) 5.60 Warrants expired and cancellation (496) 12.07 Outstanding as of December 31, 2013 20,116 5.23 Warrants issued in connection with conversion of Cognate accounts payable* 2,226 4.00 Warrants issued to Cognate for services* 4,760 4.00 Warrants issued for services 17 6.33 Warrants issued in connection with common stock issued 150 5.00 Warrants exercised on a cashless basis (73) - Warrants exercised for cash (1,309) 3.63 Warrants issued to Cognate in connection with common stock issued for cash* 281 4.00 Over-allotment rights issued in connection with registered direct offering 2,273 7.50 Warrants issued to placement agent in connection with registered direct offering 113 8.25 Warrants issued in connection with registered direct offering 2,735 5.15 Warrants canceled (2,273) 7.50 Warrants adjustment for prior period 419 6.43 Expired and canceled in fourth quarter 2014 (50) 8.29 Outstanding as of December 31, 2014 29,385 4.72 Warrants granted 1,953 4.51 Warrants exercised for cash (1,678) 4.25 Warrants exercised on a cashless basis* (304) 3.96 Warrant adjustment due to Cognate price reset 62 3.35 Warrants expired and cancellation (2,431) 4.82 Adjustment related to prior issued warrants 280 4.41 Outstanding as of December 31, 2015 ** 27,267 $ 4.40 *The warrants contain “down round protection” and the Company classifies these warrant instruments as liabilities at their fair value and adjusts the instruments to fair value at each reporting period. ** Approximately 14,323,003 3.3 4.0

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block]	The Company’s future minimum lease payments are as follows as of December 31, 2015 (in thousands): Office Leases Germany U.S. 2016 $ 67 $ 309 2017 67 318 2018 - 81 Total $ 134 $ 708

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	The tax effects of temporary differences and tax loss and credit carry forwards that give rise to significant portions of deferred tax assets and liabilities at December 31, 2015 and 2014 are comprised of the following (in thousands): As of As of December 31, 2015 December 31, 2014 Deferred tax asset Net operating loss carryforward $ 180,927 $ 133,684 Research and development credit carry forwards 12,661 $ 9,911 Stock based compensation and other 24,759 26,510 Total deferred tax assets 218,347 170,105 Valuation Allowance (218,347) (170,105) Deferred tax asset, net of allowance $ - $ -
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	The expected tax expense (benefit) based on the U.S. federal statutory rate is reconciled with actual tax expense (benefit) as follows: (dollars in thousands) For year ended For year ended December 31, 2015 December 31, 2014 Statutory federal income tax rate 34.0 % 34.0 % State taxes, net of federal tax benefit 5.4 % 5.4 % Other, net 5.8 % -0.4 % Research and development credits 2.6 % 4.4 % Change in valuation allowance -47.8 % -43.4 % Income tax provision (benefit) 0.0 % 0.0 %
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	For year ended For year ended December 31, 2015 December 31, 2014 Federal Current $ - $ - Deferred 41,583 49,912 State Current - - Deferred 6,659 7,993 Change in valuation allowance (48,242) (57,905) Income tax provision (benefit) $ - $ -

Selected Quarterly Financial 31

Selected Quarterly Financial Data (Tables)	12 Months Ended
	Dec. 31, 2015
Quarterly Financial Information Disclosure [Abstract]
Schedule of Quarterly Financial Information [Table Text Block]	The following table contains quarterly financial information for fiscal years 2015 and 2014. The Company believes that the following information reflects all normal recurring adjustments necessary for a fair statement of the information for the periods presented. First Second Third Fourth (in thousands, except per share data) Quarter Quarter Quarter Quarter 2015 Research grant and other $ 194 $ 391 $ 291 $ 863 Operating expenses $ 23,025 $ 39,245 $ 13,504 $ 52,249 Other income/(expense) $ (23,602) $ (27,991) $ 35,828 $ 27,308 Net (loss)/income $ (46,433) $ (66,845) $ 22,615 $ (24,078) Basic net (loss)/income per common share $ (0.67) $ (0.88) $ 0.29 $ (0.27) Diluted net (loss)/income per common share $ (0.67) $ (0.88) $ 0.25 $ (0.27) 2014 Research grant and other $ - $ - $ 582 $ 872 Operating expenses $ 23,682 $ 25,427 $ 27,190 $ 26,298 Other income/(expense) $ (22,359) $ (438) $ 5,565 $ (17,259) Net loss $ (46,041) $ (25,865) $ (21,043) $ (42,685) Basic and diluted net loss per common share $ (0.88) $ (0.45) $ (0.35) $ (0.64)

Liquidity, Financial Conditio32

Liquidity, Financial Condition and Management Plans (Details Textual) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Net Cash Provided By (Used In) Operating Activities									$ (78,608)	$ (54,576)	$ (37,800)
Cash Equivalents, at Carrying Value	$ 24,100								24,100
Current Assets Less Payables	40,700								40,700
Convertible Notes Payable Related Parties	5,500								5,500
Share Based Compensation Aggregate Non Cash Charges For The Non Cash Interest Associated With The Accretion Of Our Convertible Notes Discount Net									29,800
Noncash Derivative Liability	28,000								28,000
Derivative Liability	40,700								40,700
Net Income (Loss) Attributable To Parent	$ (24,078)	$ 22,615	$ (66,845)	$ (46,433)	$ (42,685)	$ (21,043)	$ (25,865)	$ (46,041)	$ (114,741)	$ (135,634)	$ (65,789)

Summary of Significant Accoun33

Summary of Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Summary of Significant Accounting Policies [Line Items]
Research and Development Expense	$ 103,120	$ 85,637	$ 43,906
Deferred Finance Costs, Net	900
Accumulated Amortization, Deferred Finance Costs	1,200
Cash payments for services	5,500	5,700
Accrued Environmental Loss Contingencies, Noncurrent	6,200
Site Contingency, Loss Exposure in Excess of Accrual, High Estimate	4,500
Site Contingency, Loss Exposure in Excess of Accrual, Low Estimate	32,000
Site Contingency, Loss Exposure in Excess of Accrual, Best Estimate	$ 6,200
Property, Plant and Equipment, Useful Life	15 years
Share-Based Compensation	$ 0	0	1,350
Common Stock Warrants Outstanding	12,433,310
Foreign Currency Transaction Gain (Loss), Realized	$ 20	23	0
Foreign Currency Gain (Loss) [Member]
Summary of Significant Accounting Policies [Line Items]
Foreign Currency Transaction Gain (Loss), Realized	67
Cognate Bioservices [Member]
Summary of Significant Accounting Policies [Line Items]
Research and Development Expense	78,500	61,000	26,800
Share-Based Compensation	$ 40,800	$ 21,300	$ 2,300

Fair Value Measurements (Detail

Fair Value Measurements (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability	$ 27,982	$ 44,742
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability	0	0
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability	0	0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability	$ 27,982	$ 44,742

Fair Value Measurements (Deta35

Fair Value Measurements (Details 1) - Warrant Liability [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance	$ 44,742	$ 8,688
Additions during the period		20,992
Change in fair value	(15,676)	15,062
Cashless warrants exercise	(521)
Warrants exercised for cash	(264)
Redeemable security settlement	(299)
Balance	$ 27,982	$ 44,742

Fair Value Measurements (Deta36

Fair Value Measurements (Details 2) - Quantitative Information One [Member] - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Strike price	$ 3.49	$ 3.54
Contractual term (years)	3 years 1 month 6 days	4 years 1 month 6 days
Volatility (annual)	86.90%	70.90%
Risk-free rate	1.30%	1.80%
Dividend yield (per share)	0.00%	0.00%

Fair Value Measurements (Deta37

Fair Value Measurements (Details 3) - Warrant [Member]	12 Months Ended
	Dec. 31, 2015$ / shares
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Strike price	$ 4.30
Contractual term (years)	2 years 1 month 6 days
Volatility (annual)	74.60%
Risk-free rate	0.50%
Dividend yield (per share)	0.00%

Fair Value Measurements (Deta38

Fair Value Measurements (Details Textual)	12 Months Ended
	Dec. 31, 2015USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value Adjustment of Warrants	$ 184,000

Share-based Compensation (Detai

Share-based Compensation (Details)	12 Months Ended
	Dec. 31, 2015$ / shares
Quantitative Information Eleven [Member]
Date of valuation	Jul. 17, 2014
Strike price	$ 4
Volatility (annual)	5.00%
Risk-free rate	78.20%
Contractual term (years)	1 year 8 months 12 days
Dividend yield (per share)	0.00%
Quantitative Information Fourteen [Member]
Date of valuation	Dec. 31, 2015
Strike price	$ 3.35
Volatility (annual)	3.50%
Risk-free rate	86.90%
Contractual term (years)	1 year 4 months 24 days
Dividend yield (per share)	0.00%

Share-based Compensation (Det40

Share-based Compensation (Details Textual) - USD ($)	1 Months Ended							3 Months Ended									12 Months Ended			93 Months Ended
	Oct. 22, 2015	Oct. 19, 2015	Jul. 17, 2014	Jan. 17, 2014	Nov. 30, 2013	Aug. 08, 2013	Apr. 30, 2013	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense																	$ 2,000,000	$ 8,700,000
Stock Issued During Period, Shares, New Issues				5,101,366		4,477,612										316,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized																	$ 1,400,000			$ 1,400,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition																	1 year
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value																	$ 3.2
Warrants Issued During Period			2,325,467																	14,323,003
Warrants Expiration Period			5 years
Warrants Initial Exercise Price			$ 4
Investment Warrants, Exercise Price			$ 3.08		$ 6		$ 4.29										$ 2.92
Lock Up Agreement Description			The Company also entered into a Lock-Up Agreement with Cognate BioServices on January 17, 2014, under which Cognate BioServices agreed to have all of the shares that are issued as part of the Cognate BioServices Agreements (“Lock-Up Shares”) locked up for up to 36 months, in return for 15% warrant coverage for each 6-month period of lock-up, on the same terms as the warrants in the Cognate BioServices Agreements. During the lock-ups, the Lock-Up Shares may not be sold or traded on the market. These lock-up terms are subject to the same most favored nation treatment as provided in the Cognate BioServices Agreements.
Share-Based Compensation																	$ 0	0	$ 1,350,000
Stock Issued During Period, Shares, Issued for Services											14,519	24,924	238,496	141,330	14,326	178,504
Stock Issued During Period, Shares, Other									80,068	109,868
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period		8,052,092
Stock Issued During Period, Value, Issued for Services											$ 94,999	$ 155,607	$ 1,600,000			$ 600,000	3,389,000
Cognate Bioservices [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense		$ 38,800,000															$ 2,700,000
Stock Issued During Period, Shares, New Issues		8,052,092
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period																	3 years
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested																	$ 2,000,000	8,700,000
Share-Based Compensation																	$ 40,800,000	$ 21,300,000	$ 2,300,000
Stock Issued During Period, Shares, Issued for Services								8,100,000									318,116
Cognate [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Issued for Services	681,884	681,884
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period		8,052,092
Stock Issued During Period, Value, Issued for Services	$ 3,800,000	$ 3,800,000
Others [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-Based Compensation																	$ 700,000
Stock Issued During Period, Shares, Other																	85,228

Property and Equipment (Details

Property and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment, Gross	$ 46,373	$ 40,159
Less: accumulated depreciation	(216)	(160)
Property, Plant and Equipment, Net	46,157	39,999
Leasehold improvements [Member]
Property, Plant and Equipment, Gross	69	69
Office furniture and equipment [Member]
Property, Plant and Equipment, Gross	25	25
Computer equipment and software [Member]
Property, Plant and Equipment, Gross	598	137
Construction in Progress [Member]
Property, Plant and Equipment, Gross	$ 45,681	$ 39,928

Property and Equipment (Detai42

Property and Equipment (Details Textual) € in Millions	Dec. 09, 2014USD ($)a	Dec. 09, 2014EUR (€)	Aug. 19, 2014USD ($)a	Aug. 19, 2014EUR (€)	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)
Depreciation					$ 56,000	$ 12,000
Accrued Environmental Loss Contingencies, Noncurrent					6,200,000
UK Facility [Member]
Environmental Costs Recognized, Capitalized	$ 2,400,000				$ 5,800,000	$ 11,500,000
Payments to Acquire Businesses, Gross	$ 7,900,000	€ 5	$ 20,800,000	€ 13
Professional Fees			$ 2,600,000
Area of Land | a	12		25
Accrued Environmental Loss Contingencies, Noncurrent			$ 6,200,000

Notes Payable (Details)

Notes Payable (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Contractual interest	$ 640	$ 321
Accelerated interest due to the conversion of convertible senior notes into common stock	763	0
Amortization of debt issuance costs	363	157
Accelerated amortization of debt issuance cost due to the conversion of convertible senior notes into common stock	302	0
Total interest expense on the convertible senior notes	$ 2,068	$ 478

Notes Payable (Details 1)

Notes Payable (Details 1) - USD ($) $ in Thousands		Dec. 31, 2015	Dec. 31, 2014
Debt Instrument [Line Items]
Notes payable - current		$ 934	$ 934
Convertible notes payable, net - current		135	188
Notes payable		50	50
Total notes payable, net		1,119	1,172
Notes Payable Current, Unsecured, Issued One [Member]
Debt Instrument [Line Items]
Notes payable - current	[1]	934	934
Convertible Notes Payable Current, Unsecured, Issued One [Member]
Debt Instrument [Line Items]
Convertible notes payable, net - current	[2]	135	135
Convertible Notes Payable Current Unsecured Issued Two [Member]
Debt Instrument [Line Items]
Convertible notes payable, net - current		0	53
Note Payable [Member]
Debt Instrument [Line Items]
Notes payable	[3]	$ 50	$ 50
[1]	This $0.934 million note, which was originally due in July 2011 is currently under dispute with the creditor as to the validity of the note payable balance, which the Company believes has already been paid in full and is not outstanding.
[2]	This $0.135 million note as of December 31, 2015 consists of two separate 6% notes in the amounts of $0.110 million and $0.025 million. In regard to the $0.110 million note, the Company has made ongoing attempts to locate the creditor to repay or convert this note, but has been unable to locate the creditor to date. In regard to the $0.025 million note, the holder has elected to convert these notes into equity, the Company has delivered the applicable conversion documents to the holder, and the Company is waiting for the holder to execute and return the documents.
[3]	This $0.050 million demand note as of December 31, 2015 is held by an officer of the Company. The holder has made no demand for payment, but reserves the right to make a demand at any time.

Notes Payable (Details Textual)

Notes Payable (Details Textual) $ / shares in Units, € in Thousands	Oct. 08, 2015USD ($)	Nov. 20, 2015USD ($)$ / sharesshares	Feb. 13, 2015USD ($)	Nov. 17, 2014USD ($)	Aug. 19, 2014USD ($)$ / shares	Apr. 30, 2013USD ($)	Jun. 30, 2015USD ($)shares	Sep. 30, 2014USD ($)	Dec. 31, 2015USD ($)$ / sharesshares	Dec. 31, 2014USD ($)shares	Dec. 31, 2013USD ($)	Oct. 22, 2015USD ($)	Feb. 13, 2015EUR (€)	Nov. 17, 2014EUR (€)
Debt Instrument [Line Items]
Debt Conversion, Converted Instrument, Amount							$ 4,500,000	$ 7,900,000		$ 16,800,000	$ 13,500,000
Debt Conversion, Converted Instrument, Shares Issued | shares							701,033
Proceeds from Issuance of Private Placement					$ 17,500,000	$ 10,000,000			$ 0	2,059,000	0
Debt Instrument, Convertible, Conversion Price | $ / shares					$ 7.30
Proceeds from Issuance or Sale of Equity					$ 16,200,000
Repayments of Other Long-term Debt									0	2,625,000	$ 0
Deferred Finance Costs, Net									900,000
Repayments of Notes Payable										20,000
Interest Expense, Debt									763,000	0
Write off of Deferred Debt Issuance Cost									302,000	0
Mortgages [Member]
Debt Instrument [Line Items]
Interest Expense, Debt									2,000,000	200,000
Write off of Deferred Debt Issuance Cost									600,000	100,000
Second Mortgage [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage				12.00%										12.00%
Short-term Debt			$ 12,000,000	$ 10,000,000									€ 7,750	€ 6,250
Senior Convertible Notes [Member]
Debt Instrument [Line Items]
Debt Conversion, Converted Instrument, Amount									$ 6,500,000
Debt Conversion, Converted Instrument, Shares Issued | shares									1,023,535
Percentage Of Initial Purchase Price									30.00%
Repayments of Other Long-term Debt									$ 2,600,000
Debt Conversion, Description									The Senior Notes are due on August 15, 2017, and are not convertible during the first three months, unless the current stock price is greater than 150% of the conversion price. Thereafter, the Senior Notes are convertible at any time
Escrow Deposit									$ 1,200,000
Cognate Note [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage												8.00%
Debt Instrument, Face Amount												$ 1,000,000
Debt Instrument, Periodic Payment, Total		$ 1,009,644
Goldman Note [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	8.00%
Debt Instrument, Face Amount	$ 400,000
Debt Instrument Repayment, Percentage of Warrants	35.00%
Debt Instrument, Periodic Payment, Total		$ 403,858
Warrant Issued Term		5 years
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right | shares		28,384
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares		$ 4.98
Minimum [Member] | Senior Convertible Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Convertible, Conversion Price | $ / shares									$ 6.60
Maximum [Member] | Senior Convertible Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Convertible, Conversion Price | $ / shares									$ 7.30
Convertible Notes Payable Current, Unsecured, Issued One [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage									12.00%
Convertible Notes Payable Current Unsecured Issued Two [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage									6.00%
Notes Payable [Member]
Debt Instrument [Line Items]
Debt Conversion, Converted Instrument, Amount										$ 200,000
Debt Conversion, Converted Instrument, Shares Issued | shares										70,000
12% Coupon [Member] | Mortgages [Member]
Debt Instrument [Line Items]
Interest Expense, Debt									$ 1,400,000	$ 100,000
Bridge Loan [Member]
Debt Instrument [Line Items]
Initial Loan Amount Received			5,000,000	7,000,000									€ 3,250	€ 4,500
Deferred Finance Costs, Net			$ 100,000	$ 300,000
Bridge Loan [Member] | Second Mortgage [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage			12.00%										12.00%
Debt Instrument, Term			1 year 6 months	2 years

Net Loss per Share Applicable46

Net Loss per Share Applicable to Common Stockholders (Details) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities	30,581	33,415	19,232
Common Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities	1,551	1,551	1,551
Common stock warrants equity treatment [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities	14,834	16,830	15,321
Common stock warrants liability treatment [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities	12,433	12,555	2,233
Convertible Notes [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities	1,763	2,479	127

Related Party Transactions (Det

Related Party Transactions (Details Textual) - USD ($)	1 Months Ended										3 Months Ended										12 Months Ended			93 Months Ended
	Nov. 20, 2015	Oct. 22, 2015	Oct. 19, 2015	Sep. 23, 2015	Apr. 30, 2015	Jul. 17, 2014	Jun. 30, 2014	Nov. 30, 2013	Jul. 31, 2013	Mar. 31, 2013	Sep. 30, 2015	Jun. 30, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2015	Jan. 17, 2014
Related Party Transaction [Line Items]
Debt Conversion, Converted Instrument, Amount												$ 4,500,000		$ 7,900,000								$ 16,800,000	$ 13,500,000
Debt Conversion, Converted Instrument, Shares Issued (in shares)												701,033
Share-based Compensation																					$ 0	0	1,350,000
Lock Up Period Of Conversion Feature																					36 months
Amount Of Reduction Under Short Swing													$ 448,000
Stock Issued During Period, Value, Issued for Services														$ 94,999	$ 155,607	$ 1,600,000			$ 600,000		$ 3,389,000
Stock Issued During Period, Shares, Issued for Services														14,519	24,924	238,496	141,330	14,326	178,504
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period			8,052,092
Warrants Issued During Period						2,325,467																		14,323,003
Stock Issued During Period, Value, New Issues								$ 27,000,000											$ 900,000	$ 900,000	81,662,000
Loss Contingency, Damages Awarded, Value				$ 500,000
Loss Contingency, Damages Sought, Value				$ 125,000
Loss Contingency, Damages Sought, Estimated Value					$ 1,400,000
Inducement Expenses																$ 5,300,000	$ 2,700,000
Warrant Issuable			3,812,555
Cognate Note [Member]
Related Party Transaction [Line Items]
Debt Instrument, Face Amount		$ 1,000,000
Debt Instrument, Interest Rate, Stated Percentage		8.00%
Debt Instrument, Periodic Payment, Total	$ 1,009,644
Condition Two [Member]
Related Party Transaction [Line Items]
Contingent Liability DCVax-L Manufacturing Services Agreement Amount																									$ 3
Common Stock [Member]
Related Party Transaction [Line Items]
Debt Conversion, Converted Instrument, Shares Issued (in shares)											322,502
Stock Issued During Period, Value, Issued for Services																					$ 0
Stock Issued During Period, Shares, Issued for Services																					403
Stock Issued During Period, Value, New Issues								$ 27,000,000													$ 14,000
Inducement Expenses																$ 2,800,000
Toucan Capital and Toucan Partners [Member]
Related Party Transaction [Line Items]
Proceeds from Short-term Debt										$ 200,000
Cognate Bioservices [Member]
Related Party Transaction [Line Items]
Debt Conversion, Converted Instrument, Amount									$ 11,600,000													16,000,000
Cash Consideration Per Share (in dollars per share)									$ 4
Accounts Payable, Related Parties													$ 5,700,000								5,500,000	5,700,000		$ 5,500,000
Share-based Compensation																					$ 40,800,000	21,300,000	2,300,000
Lock Up Period Of Conversion Feature																					3 years
Repayments of Short-term Debt									$ 1,200,000
Stock Issued During Period, Shares, Issued for Services												8,100,000									318,116
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period																					3 years
Payments to Acquire in Process Research and Development																					$ 78,500,000	$ 61,000,000	$ 26,800,000
Inducement Expenses																	$ 1,500,000
Cognate Bioservices [Member] | Accounts Payable [Member]
Related Party Transaction [Line Items]
Debt Conversion, Converted Instrument, Amount															$ 2,900,000
Debt Conversion, Converted Instrument, Shares Issued (in shares)									2,900,000
Cognate Bioservices [Member] | Condition Two [Member]
Related Party Transaction [Line Items]
Contingent Liability DCVax-L Manufacturing Services Agreement Amount																									2
Cognate Bioservices [Member] | Condition Three [Member]
Related Party Transaction [Line Items]
Contingent Liability DCVax-L Manufacturing Services Agreement Amount																									$ 5
Cognate Bioservices [Member] | Warrant [Member]
Related Party Transaction [Line Items]
Debt Conversion, Converted Instrument, Shares Issued (in shares)																						2,200,000	2,400,000
Investors Warrants Exercisable							281,250
Warrants Issued During Period							2,300,000
Inducement Expenses							$ 2,400,000
Cognate Bioservices [Member] | Common Stock [Member]
Related Party Transaction [Line Items]
Debt Conversion, Converted Instrument, Shares Issued (in shares)							562,500															4,200,000	4,700,000
Stock Issued During Period, Shares, Issued for Services												318,116
Stock Issued During Period, Value, New Issues							$ 562,500
Cognate [Member]
Related Party Transaction [Line Items]
Lock Up Period Of Conversion Feature			3 years
Stock Issued During Period, Value, Issued for Services		$ 3,800,000	$ 3,800,000
Stock Issued During Period, Shares, Issued for Services		681,884	681,884
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period			8,052,092
Executive Officer [Member]
Related Party Transaction [Line Items]
Proceeds from Short-term Debt										$ 200,000

Stockholders' Deficit (Details)

Stockholders' Deficit (Details) shares in Thousands		12 Months Ended
		Dec. 31, 2015$ / shares$ / Unitshares		Dec. 31, 2014$ / shares$ / Unitshares	Dec. 31, 2013$ / shares$ / Unitshares
Shareholders Deficit [Line Items]
Number of Warrants, Outstanding as of December 31, 2014		29,385		20,116	12,086
Number Of Warrants - warrants granted		1,953
Number of Warrants - warrants issued in connection with conversion of Cognate accounts payable	[1]			2,226	2,356
Number Of Warrants - Warrants issued for services				17	183
Number Of Warrants - Warrants issued in connection with April 2013 registered direct offering					1,026
Number Of Warrants - Warrants issued in connection with August 2013 registered direct offering					2,239
Number Of Warrants - Warrants issued in connection with October 2013 registered direct offering					2,815
Number of Warrants - warrants issued in connection with registered direct offering				2,735
Number of Warrants - warrants issued to placement agent in connection with registered direct offering				113	128
Number Of Warrants - Warrant issued for extension of redeemable securities					126
Number of Warrants, Warrants exercised for cash		(1,678)		(1,309)	(179)
Number of Warrants, Warrants exercised on a cashless basis		(304)	[1]	(73)	(168)
Number Of Warrants - warrants issued to Cognate in connection with common stock issued for cash	[1]			281
Number Of Warrants - Over-allotment rights issued in connection with registered direct offering				2,273
Number of Warrants, Expired and cancelled		(2,431)		(50)	(496)
Number of Warrants, Warrant adjustment due to Cognate price reset		62
Number of Warrants, Adjustment related to prior issued warrants		280		419
Number of Warrants - warrants issued in connection with common stock issued				150
Number Of Warrants - Warrants issued to Cognate for services				4,760
Number Of Warrants - Warrants canceled				(2,273)
Number of Warrants, Outstanding as of December 31, 2015		27,267	[2]	29,385	20,116
Weighted Average Exercise Price - Outstanding | $ / shares		$ 4.72		$ 5.23	$ 6.18
Weighted Average Exercise Price - warrants granted | $ / shares		$ 4.51
Weighted Average Exercise Price - warrants issued in connection with conversion of Cognate accounts payable | $ / Unit	[1]			4	4
Weighted Average Exercise Price - Warrants issued to Cognate for services | $ / Unit				4
Weighted Average Exercise Price - warrants issued for services | $ / Unit				6.33	5.83
Weighted Average Exercise Price - Warrants issued in connection with April 2013 registered direct offering | $ / shares					$ 4.29
Weighted Average Exercise Price - warrants issued in connection with August 2013 registered direct offering | $ / shares					4
Weighted Average Exercise Price - warrants issued in connection with October 2013 registered direct offering | $ / shares					6
Weighted Average Exercise Price - warrants issued in connection with registered direct offering | $ / shares				$ 5.15
Weighted Average Exercise Price - warrants issued to placement agent in connection with registered direct offering | $ / shares				$ 8.25	4.29
Weighted Average Exercise Price - Warrant issued for extension of redeemable securities | $ / shares					$ 5.01
Weighted Average Exercise Price - Warrants exercised for cash		4.25		3.63	3.35
Weighted average exercise Price - Warrants exercised on a cashless basis		3.96	[1]	0	5.60
Weighted Average Exercise Price warrants issued to Cognate in connection with common stock issued for cash | $ / shares	[1]			$ 4
Weighted Average Exercise Price - over-allotment rights issued in connection with registered direct offering | $ / shares				$ 7.50
Weighted Average Exercise Price - Expired and cancelled		4.82		8.29	12.07
Weighted Average Exercise Price - warrants issued in connection with common stock issued | $ / shares				$ 5
Weighted Average Exercise Price - Adjustment related to prior issued warrants | $ / Unit		4.41		6.43
Weighted Average Exercise Price - Warrant adjustment due to Cognate price reset | $ / Unit		3.35
Weighted Average Exercise Price - Warrants cancelled | $ / Unit				7.50
Weighted Average Exercise Price - Outstanding | $ / shares		$ 4.40	[2]	$ 4.72	$ 5.23
[1]	The warrants contain “down round protection” and the Company classifies these warrant instruments as liabilities at their fair value and adjusts the instruments to fair value at each reporting period.
[2]	Approximately 14,323,003 warrants issued to Cognate, during the 8-year period from 2008 through 2015, with a weighted average exercise price and remaining contractual term of $3.3 and 4.0 years, respectively. The weighted average exercise price gives effect to adjustments related to the most favored nation clause in these warrants.

Stockholders' Deficit (Details

Stockholders' Deficit (Details Textual) - USD ($)	1 Months Ended																					3 Months Ended											12 Months Ended			93 Months Ended
	Dec. 24, 2015	Dec. 22, 2015	Oct. 31, 2015	Oct. 19, 2015	May. 01, 2015	Apr. 08, 2015	Apr. 02, 2015	Nov. 19, 2014	Nov. 17, 2014	Oct. 06, 2014	Sep. 19, 2014	Aug. 19, 2014	Aug. 12, 2014	Jul. 17, 2014	Jun. 30, 2014	Apr. 09, 2014	Jan. 17, 2014	Nov. 30, 2013	Aug. 08, 2013	Jul. 31, 2013	Apr. 30, 2013	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2015
Shareholders Deficit [Line Items]
Stock Issued During Period, Shares, Issued for Services																										14,519	24,924	238,496	141,330	14,326	178,504
Inducement Expenses																												$ 5,300,000	$ 2,700,000
Redeemable Shares Number																												1,444,788	41,667	366,667
Stock Issued During Period Shares Exercise of Warrant																						116,675						721,827
Stock Issued During Period Value Exercise of Warrant																												$ 2,700,000
Stock Issued During Period, Value, Issued for Services																										$ 94,999	$ 155,607	1,600,000			$ 600,000		$ 3,389,000
Stock Issued During Period, Shares, Conversion of Convertible Securities										2,272,727						2,272,727
Stock Issued During Period, Value, Conversion of Convertible Securities, Net of Adjustments, Total										$ 11,500,000						$ 15,000,000			$ 15,000,000
Fair value of Warrants at Issuance Date																								$ 500,000		$ 3,800,000
Induced Conversion Of Convertible Debt Expense																													$ 200,000				0	$ 18,905,000	$ 10,599,000
Reclassification Of Equity Instruments, Shares											49,107		3,013
Shares Issued, Price Per Share							$ 7.40			$ 5.05						$ 6.60
Proceeds from Shares Payable													$ 15,000														$ 1,400,000	1,400,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period																								888,187		497,133	92,100
Proceeds from Warrant Exercises																		$ 5,600,000				$ 800,000	$ 3,100,000	$ 3,700,000		$ 1,700,000	$ 395,000						7,430,000	4,817,000	595,000
Debt Conversion, Converted Instrument, Amount																							$ 4,500,000			$ 7,900,000								16,800,000	13,500,000
Stock Issued During Period, Value, Share-based Compensation, Gross																																	40,765,000	8,665,000
Value of Notes Converted to Common stock																												$ 200,000
Number of common shares from Notes conversion																												70,000
Reclassification of redeemable shares to Equity, Value																												$ 8,900,000
Warrants Issued During Period														2,325,467																						14,323,003
Warrants Issued, Weighted Average Exercise Price Per Warrant																																				$ 3.3
Stock Issued During Period, Value, New Issues																		$ 27,000,000													$ 900,000	$ 900,000	81,662,000
Stock Issued During Period, Shares, New Issues																	5,101,366		4,477,612												316,000
Stock Issued During Period For Convertible Notes																																359,000
Fair Value Price Per Share																																$ 2.60
Stock Issued During Period, Shares, Restricted Stock Award, Gross																																235,593
Convertible Notes Payable																																$ 900,000
Fair Value Of Common Stock Issued For Redemption of Redeemable Securities																								$ 300,000
Stock Issued During Period New Issues Price Per Share																															$ 2.90
Common Stock Closing Market Price																		$ 4.80			$ 3.90									$ 3.46
Common Stock Purchase Warrants																		2,815,104
Warrants Offering Cost																		$ 2,000,000			$ 800,000
Number Of Common Stock Warrants Exercisable																												41,310	179,094		168,354
Proceeds from Issuance of Private Placement												$ 17,500,000									$ 10,000,000												$ 0	2,059,000	0
Investment Warrants, Exercise Price														$ 3.08				$ 6			$ 4.29												$ 2.92
Fair Value Of Common Stock Issued In Exchange For Services																													$ 700,000	$ 100,000
Stock Issued During Period Shares Issued In Exchange For Redemption Period Extension																													733,104	30,000
Stock Issued During Period For Convertible Notes In 2012																														164,155
Restricted Stock Fair Value Per Share																													$ 3.68
Potential Redeemable Shares Eligible																													383,315
Warrants Exercise Price																		$ 6
Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests																													$ 1,900,000						1,900,000
Proceeds from Issuance of Warrants																		$ 25,000,000															$ 0	$ 2,250,000	$ 0
Stock Issued During Period, Shares, Other																								80,068	109,868
Sale of Stock, Price Per Share																			$ 3.35
Stock Issued During Period, Shares, Cashless Exercise of Warrants																								385,000
Stock Issued During Period, Shares, Acquisitions							5,405,405
Common Stock, Par Or Stated Value Per Share							$ 0.001																		$ 0.001								$ 0.001	$ 0.001		$ 0.001
Stock Issued During Period, Value, Acquisitions							$ 40,000,000
Stock Issued During Period, Exercise Of Warrants																							723,422
Stock Issued During Period, Shares, Extinguishment of warrant liabilities																						57,500	9,200
Stock Issued During Period, Value, Extinguishment of warrant liabilities																							$ 60,000
Debt Conversion, Converted Instrument, Shares Issued																							701,033
Allocated Share-based Compensation Expense																																	$ 2,000,000	$ 8,700,000
Fair Value Of Common Stock Issued In Exchange For Redemption Period Extension																						$ 100,000
2014 Convertible Notes Member
Shareholders Deficit [Line Items]
Debt Conversion, Converted Instrument, Amount																						$ 2,000,000
Service Agreement [Member]
Shareholders Deficit [Line Items]
Stock Issued During Period, Shares, Issued for Services								38,400
Sale of Stock, Price Per Share								$ 5.15
Deferred Finance Costs, Noncurrent, Net																									$ 197,376									197,376
Sale of Stock Closing One [Member]
Shareholders Deficit [Line Items]
Stock Issued During Period, Shares, Acquisitions					3,851,351	1,554,054
Stock Issued During Period, Value, Acquisitions					$ 28,500,000	$ 11,500,000
Sale of Stock, Transaction Date					May 1, 2015	Apr. 8, 2015
Investor [Member]
Shareholders Deficit [Line Items]
Inducement Expenses																									$ 400,000
Stock Issued During Period, Shares, Conversion of Convertible Securities										2,272,727																1,398,625
Stock Issued During Period, Value, Conversion of Convertible Securities, Net of Adjustments, Total																$ 17,050,000										$ 4,500,000
Shares Issued, Price Per Share										$ 7.50						$ 7.50
Stock Issued During Period, Shares, New Issues																2,272,727					2,564,103
Common Stock Purchase Warrants																					1,025,641
Warrants Offering Cost																			$ 1,200,000
Number Of Common Stock Warrants Exercisable																			1,119,403
Investment Warrants, Exercise Price																			$ 4
Description Of Unit In Private Placement																			Each unit consists of one share of common stock, warrant to purchase 0.25 of a share of common stock and one over-allotment warrant to purchase 0.25 of a share of common stock
Investor [Member] | Issue One [Member]
Shareholders Deficit [Line Items]
Stock Issued During Period, Shares, Conversion of Convertible Securities																										435,202
Shares Issued, Price Per Share																										$ 5.17
Investor [Member] | Issue Two [Member]
Shareholders Deficit [Line Items]
Stock Issued During Period, Shares, Conversion of Convertible Securities																										448,207
Shares Issued, Price Per Share																										$ 5.02
Single Institutional Investor [Member]
Shareholders Deficit [Line Items]
Stock Issued During Period, Value, Share-based Compensation, Gross																											$ 435,540
Stock Issued During Period, Shares, Share-based Compensation, Gross																											58,614
Stock Issued During Period, Value, New Issues																					$ 1,000,000
Stock Issued During Period, Shares, New Issues																					281,690
Stock Issued During Period New Issues Price Per Share																					$ 3.55
Cognate Bioservices [Member]
Shareholders Deficit [Line Items]
Stock Issued During Period, Shares, Issued for Services																							8,100,000										318,116
Stock Issued During Period For Convertible Accounts																													1,818,000
Fair Value Of Common Stock For Convertible Accounts																													$ 6,700,000
Inducement Expenses																													$ 1,500,000
Induced Conversion Of Convertible Debt Expense																										$ 8,300,000	$ 2,500,000
Debt Conversion, Converted Instrument, Amount																				$ 11,600,000														$ 16,000,000
Stock Issued During Period, Shares, New Issues				8,052,092
Stock Issued During Period For Convertible Notes																													150,000
Fair Value Of Common Stock For Convertible Notes																													$ 500,000
Allocated Share-based Compensation Expense				$ 38,800,000																													$ 2,700,000
Cognate Bioservices [Member] | Accounts Payable [Member]
Shareholders Deficit [Line Items]
Fair value of Warrants at Issuance Date															$ 1,100,000												1,100,000
Induced Conversion Of Convertible Debt Expense																										$ 4,500,000	1,400,000
Debt Conversion, Converted Instrument, Amount																											$ 2,900,000
Debt Conversion, Converted Instrument, Shares Issued																				2,900,000
Multiple Investors [Member]
Shareholders Deficit [Line Items]
Stock Issued During Period Shares Issued For Cash 1																						2,566
Stock Issued During Period, Exercise Of Warrants																							183,895
individual Investors [Member]
Shareholders Deficit [Line Items]
Stock Issued During Period Shares Exercise of Warrant																							85,228
Stock Issued During Period, Value, Share-based Compensation, Gross																							$ 700,000
Woodford [Member]
Shareholders Deficit [Line Items]
Stock Issued During Period, Shares, Issued for Services			681,884
Stock Issued During Period, Value, Issued for Services			$ 3,800,000
Sale of Stock, Price Per Share			$ 5.50
Stock Issued During Period, Shares, Acquisitions			5,454,545
Common Stock, Par Or Stated Value Per Share			$ 0.001
Stock Issued During Period, Value, Acquisitions			$ 30,000,000
Healthcare Focused Institutional Investors [Member]
Shareholders Deficit [Line Items]
Stock Issued During Period, Value, New Issues	$ 12,600,000
Proceeds from Issuance of Common Stock	$ 11,650,000
Common Stock [Member]
Shareholders Deficit [Line Items]
Stock Issued During Period, Shares, Issued for Services																																	403
Inducement Expenses																												$ 2,800,000
Stock Issued During Period, Value, Issued for Services																																	$ 0
Stock Issued During Period Shares Issued For Cash 1																																		2,273	12,954
Stock Issued During Period, Shares, Conversion of Convertible Securities																																	985
Subscription Receivable for issuance of common stock, Shares																											16,200
Cashless Exercises Of Warrants Shares																											12,533
Stock Issued During Period Shares Conversion Of Accounts Payable To Common Stock And Warrants																										1,986,205	727,291
Stock Issued During Period, Value, Share-based Compensation, Gross																																	$ 8,000	$ 5,000
Stock Issued During Period, Shares, Share-based Compensation, Gross																																	8,052	5,101
Common Stock, Share Subscribed but Unissued, Subscriptions Receivable															$ 125,550												$ 125,550
Stock Issued During Period, Value, New Issues																		$ 27,000,000															$ 14,000
Stock Issued During Period, Shares, New Issues																		5,630,208															14,360
Stock Issued During Period New Issues Price Per Share																		$ 4.80
Stock Issued During Period, Shares, Other																																		71
Debt Conversion, Converted Instrument, Shares Issued																						322,502
Common Stock [Member] | Issue One [Member]
Shareholders Deficit [Line Items]
Stock Issued During Period, Value, Issued for Services																												$ 200,000
Stock Issued During Period Shares Issued For Cash 1																												32,000
Common Stock [Member] | Investor [Member]
Shareholders Deficit [Line Items]
Shares Issued, Price Per Share											$ 5.60		$ 5.60		$ 7												$ 7
Stock Issued During Period, Value, New Issues																												$ 100,000
Stock Issued During Period, Shares, New Issues																											200,000	20,833
Common Stock [Member] | Cognate Bioservices [Member]
Shareholders Deficit [Line Items]
Stock Issued During Period, Shares, Issued for Services																							318,116
Stock Issued During Period, Value, New Issues															$ 562,500
Stock Issued During Period, Shares, New Issues																											562,500
Debt Conversion, Converted Instrument, Shares Issued															562,500																			4,200,000	4,700,000
Common Stock [Member] | Multiple Investors [Member]
Shareholders Deficit [Line Items]
Stock Issued During Period, Value, New Issues																										$ 300,000
Stock Issued During Period, Shares, New Issues																										52,120
Common Stock [Member] | individual Investors [Member]
Shareholders Deficit [Line Items]
Proceeds from Shares Payable											$ 275,000
Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants											$ 14,732
Common Stock [Member] | Healthcare Focused Institutional Investors [Member]
Shareholders Deficit [Line Items]
Shares Issued, Price Per Share		$ 3.60
Stock Issued During Period, Shares, New Issues		3,500,000
Common Stock, Par Or Stated Value Per Share		$ 0.001
Warrant [Member]
Shareholders Deficit [Line Items]
Fair Value Of Common Stock For Convertible Accounts																												$ 2,500,000
Proceeds from Warrant Exercises																													$ 600,000
Stock Issued During Period Shares Conversion Of Accounts Payable To Common Stock And Warrants																										1,100,000	363,646
Stock Issued During Period, Value, Share-based Compensation, Gross																											$ 2,300,000
Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants													$ 1,507
Warrant [Member] | Single Institutional Investor [Member]
Shareholders Deficit [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period										2,735,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value										$ 5.15
Warrant [Member] | Cognate Bioservices [Member]
Shareholders Deficit [Line Items]
Inducement Expenses															$ 2,400,000
Stock Issued During Period, Shares, Share-based Compensation, Gross																											281,250
Warrants Issued During Period															2,300,000
Debt Conversion, Converted Instrument, Shares Issued																																		2,200,000	2,400,000
Warrant [Member] | Healthcare Focused Institutional Investors [Member]
Shareholders Deficit [Line Items]
Shares Issued, Price Per Share		$ 4.50
Stock Issued During Period, Shares, New Issues		1,750,000
Conversion Of Accounts Payable To Cognate [Member]
Shareholders Deficit [Line Items]
Stock Issued During Period For Convertible Accounts																												1,481,644
Fair Value Of Common Stock For Convertible Accounts																												$ 5,900,000
Conversion Of Notes Payable One [Member]
Shareholders Deficit [Line Items]
Stock Issued During Period, Value, New Issues																														$ 500,000
Stock Issued During Period, Shares, New Issues																														184,600
Stock Issued During Period For Convertible Notes																													149,732
Convertible Notes Payable																													$ 500,000						$ 500,000
Stock Issued During Period New Issues Price Per Share																														$ 2.60
Unregistered Shares [Member]
Shareholders Deficit [Line Items]
Shares Issued, Price Per Share									$ 5.79
Stock Issued During Period, Value, New Issues									$ 25,000,000
Stock Issued During Period, Shares, New Issues									4,317,789
Conversion Of Accounts Payable [Member]
Shareholders Deficit [Line Items]
Stock Issued During Period, Value, New Issues																														$ 10,300,000
Stock Issued During Period, Shares, New Issues																														2,902,072
Stock Issued During Period New Issues Price Per Share																														$ 3.55
Additional Paid-in Capital [Member]
Shareholders Deficit [Line Items]
Stock Issued During Period, Value, Issued for Services																																	$ 3,389,000
Stock Issued During Period, Value, Share-based Compensation, Gross																																	40,757,000	$ 8,660,000
Stock Issued During Period, Value, New Issues																																	$ 81,648,000
Stock Issued During Period, Value, Extinguishment of warrant liabilities																						$ 200,000
Maximum [Member]
Shareholders Deficit [Line Items]
Warrants Issued, Weighted Average Remaining Contractual Term																																				4 years
Minimum [Member]
Shareholders Deficit [Line Items]
Warrants Issued, Weighted Average Remaining Contractual Term																																				3 years 3 months 18 days

Commitments and Contingencies50

Commitments and Contingencies (Details) $ in Thousands	Dec. 31, 2015USD ($)
Germany [Member]
Commitments And Contingencies [Line Items]
2,016	$ 67
2,017	67
2,018	0
Total	134
U.S [Member]
Commitments And Contingencies [Line Items]
2,016	309
2,017	318
2,018	81
Total	$ 708

Commitments and Contingencies51

Commitments and Contingencies (Details Textual) - USD ($)	1 Months Ended		12 Months Ended
	Oct. 28, 2013	Jul. 31, 2012	Dec. 31, 2015	Dec. 31, 2014
Commitments And Contingencies [Line Items]
Office Space Taken Under Lease Agreement	4,251 square feet	7,097 square feet
Operating Leases, Rent Expense			$ 300,000	$ 300,000
Cognate Bioservices [Member]
Commitments And Contingencies [Line Items]
Deemed Profit			(448,681)
Loss Contingency Alleges Estimated Amount			1,400,000
Litigation Settlement, Expense			500,000
Loss Contingency Accrual, Payments			125,000
Litigation Settlement, Amount			125,000
Loss Contingency Accrual, Period Increase (Decrease), Total			$ 500,000

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Deferred tax asset
Net operating loss carryforward	$ 180,927	$ 133,684
Research and development credit carry forwards	12,661	9,911
Stock based compensation and other	24,759	26,510
Total deferred tax assets	218,347	170,105
Valuation Allowance	(218,347)	(170,105)
Deferred tax asset, net of allowance	$ 0	$ 0

Income Taxes (Details 1)

Income Taxes (Details 1)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Statutory federal income tax rate	34.00%	34.00%
State taxes, net of federal tax benefit	5.40%	5.40%
Other, net	5.80%	(0.40%)
Research and development credits	2.60%	4.40%
Change in valuation allowance	(47.80%)	(43.40%)
Income tax provision (benefit)	0.00%	0.00%

Income Taxes (Details 2)

Income Taxes (Details 2) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Federal
Current	$ 0	$ 0
Deferred	41,583	49,912
State
Current	0	0
Deferred	6,659	7,993
Change in valuation allowance	(48,242)	(57,905)
Income tax provision (benefit)	$ 0	$ 0

Income Taxes (Details Textual)

Income Taxes (Details Textual) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Income Taxes [Line Items]
Computation of Corporate Tax Rate	39.40%	39.40%
Deferred Tax Assets Tax Credit Carry Forward Unused Research And Development	$ 12.7
Deferred Tax Asset Operating Loss Carry Forward	458.7
Income Tax Examination, Increase (Decrease) in Liability from Prior Year	$ 1.6

Subsequent Events (Details Text

Subsequent Events (Details Textual) - USD ($)	1 Months Ended
	Feb. 29, 2016	Jul. 17, 2014	Aug. 08, 2013
Subsequent Event [Line Items]
Warrants Expiration Period		5 years
Sale of Stock, Price Per Share			$ 3.35
Subsequent Event [Member]
Subsequent Event [Line Items]
Sale of Stock, Price Per Share	$ 1.70
Procees From Sale Of Availiable Securities Gross	$ 10,000,000
Sale of Stock, Number of Shares Issued in Transaction	5,882,353
Proceeds from Sale of Available-for-sale Securities, Total	$ 9,210,000
Subsequent Event [Member] | Series A Warrants [Member]
Subsequent Event [Line Items]
Warrants Expiration Period	5 years
Warrants Issued To Purchase Of Common Stock	2,941,177
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 2.25
Subsequent Event [Member] | Series B Warrants [Member]
Subsequent Event [Line Items]
Warrants Issued To Purchase Of Common Stock	5,882,353
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 3
Subsequent Event [Member] | Series C Warrants [Member]
Subsequent Event [Line Items]
Warrants Expiration Period	5 years
Warrants Issued To Purchase Of Common Stock	2,941,177
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 4

Selected Quarterly Financial 57

Selected Quarterly Financial Data (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Research grant and other	$ 863	$ 291	$ 391	$ 194	$ 872	$ 582	$ 0	$ 0	$ 1,739	$ 1,454	$ 809
Operating expenses	52,249	13,504	39,245	23,025	26,298	27,190	25,427	23,682	128,023	102,597	56,283
Other income/(expense)	27,308	35,828	(27,991)	(23,602)	(17,259)	5,565	(438)	(22,359)
Net (loss)/income	$ (24,078)	$ 22,615	$ (66,845)	$ (46,433)	$ (42,685)	$ (21,043)	$ (25,865)	$ (46,041)	$ (114,741)	$ (135,634)	$ (65,789)
Basic net (loss)/income per common share	$ (0.27)	$ 0.29	$ (0.88)	$ (0.67)
Diluted net (loss)/income per common share	$ (0.27)	$ 0.25	$ (0.88)	$ (0.67)
Basic and diluted net loss per common share					$ (0.64)	$ (0.35)	$ (0.45)	$ (0.88)	$ (1.48)	$ (2.29)	$ (2)